Compositions and methods for treating facioscapulohumeral muscular dystrophy (FSHD)
Patent Information
- Application Number
- JP2023532456
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-30
- Filing Date
- 2021-11-30
- Publication Date
- 2024-11-14
AI Technical Summary
There are currently no effective treatments for facioscapulohumeral muscular dystrophy (FSHD), a common inherited muscular dystrophy caused by aberrant expression of the dual homeobox 4 (DUX4) gene, which leads to muscle weakness and degeneration.
The use of U7 small nuclear RNA (U7snRNA) to inhibit DUX4 expression in muscle cells through viral vectors like adeno-associated virus (AAV), delivering U7snRNA constructs to target and silence DUX4 gene expression.
Reduces DUX4 mRNA and protein levels, ameliorating muscle cell death and muscle weakness, potentially slowing disease progression and improving muscle function.
Smart Images

Figure 00000056_0000 
Figure 00000056_0001 
Figure 00000057_0000
Abstract
Description
Technical Field
[0001] Statement of Government Interests This invention was made with government support under Grant No. AR070604 from the National Institutes of Health. The government has certain rights in this invention.
[0002] Incorporation by Reference of a Sequence Listing This application includes, as a separate part of the disclosure, a sequence listing in computer-readable form (filename: 56061_Seqlisting.txt, size: 13,671 bytes, created on November 23, 2021), which is hereby incorporated by reference in its entirety.
[0003] This disclosure relates to the field of treatment of muscular dystrophy or cancer, including, but not limited to, facioscapulohumeral muscular dystrophy (FSHD) or sarcoma. More specifically, this disclosure provides RNA interference-based products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing muscular dystrophy or cancer, including, but not limited to, FSHD or sarcoma. Specifically, this disclosure provides products and methods for inhibiting or downregulating the expression of the double homeobox 4 (DUX4) gene. More specifically, this disclosure provides U7 small nuclear RNA (U7snRNA) for inhibiting or downregulating the expression of DUX4, and methods of using the U7snRNA to inhibit or downregulate the expression of DUX4 in cells and / or in a subject having or at risk of having muscular dystrophy or cancer.
Background Art
[0004] Muscular dystrophy (MD) is a group of hereditary diseases. This group is characterized by the progressive weakness and degeneration of the skeletal muscles that control movement. Some forms of MD develop in infancy or childhood, while others may not appear until after middle age. The disorders differ in the distribution and degree of muscle weakness (some forms of MD also affect the myocardium), age of onset, rate of progression, and mode of inheritance.
[0005] Facioscapulohumeral dystrophy (FSHD) is the most commonly inherited muscular dystrophy, estimated to affect as many as 870,000 people. The classic description of FSHD symptoms includes progressive weakness in the face, shoulder girdle, and arms, but the disease can manifest more broadly, including the muscles of the torso and lower extremities. Variability is also common within individuals, and asymmetrical weakness is common. The age of onset can range from infancy to adulthood and is usually related to the severity of the disease, with earlier onset often associated with more severe weakness. Most patients with FSHD have a normal lifespan, but respiratory failure can occur, the disease can be debilitating, and about 25% of affected individuals may become wheelchair dependent by their 50s, even earlier in more severe forms of the disease, while others maintain walking ability throughout their lives.
[0006] FSHD is caused by the abnormal expression of the double homeobox 4 gene (DUX4), which produces transcription factors toxic to skeletal muscle. DUX4 normally functions during the four-cell stage of human development, but is subsequently suppressed in virtually all other tissues, except perhaps the testes and possibly the thymus. In the skeletal muscle of people with FSHD, certain genetic and epigenetic factors simultaneously enable DUX4 derepression, which then initiates several abnormal gene expression cascades, including those involved in differentiation abnormalities, oxidative stress, inflammatory infiltration, cell death, and muscle atrophy.
[0007] Despite advances in the field of FSHD, there are still no approved treatments for FSHD, and therapeutic development remains a critical need in this area. The safety and efficacy of DUX4 silencing using RNAi-based gene therapy delivered by AAV vectors have already been demonstrated in preclinical trials (Non-Patent Literature 1). Since even very small amounts of DUX4 protein can be toxic to muscle cells, it is important to develop additional DUX4 silencing strategies that can be used alone or in combination therapy, utilizing alternative mechanisms to help maximize DUX4 silencing in the patient's muscles.
[0008] Since FSHD arises from DUX4 disinhibition, the most direct pathway to therapy involves inhibiting DUX4 in muscle. Genetic regulation by U7 micronuclear RNA (U7snRNA) is one powerful approach to inhibiting DUX4. U7snRNA is an RNA molecule, a component of the micronuclear-ribonucleoprotein complex (U7snRNP), and is required for histone premRNA processing.
[0009] Viral vectors such as adeno-associated virus (AAV) have been used to deliver U7snRNA to muscles. AAV possesses unique characteristics that make it attractive as a vector for delivering foreign DNA to cells, for example in gene therapy. AAV infection of cells in culture is non-cellular degeneration, and natural infections in humans and other animals are asymptomatic and asymptomatic. Furthermore, AAV can infect many mammalian cells, giving the possibility of targeting many different tissues in vivo. In addition, AAV can transduce slow-dividing and non-dividing cells and persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in a plasmid that enables the construction of recombinant genomes. Furthermore, because the signals directing AAV replication, genomic capsid formation, and integration are contained within the ITR of the AAV genome, some or all of the approximately 4.3kb of genome inside (encoding the replication and structural capsid protein rep-cap) can be replaced by foreign DNA. The rep and cap proteins can be supplied in trans form. Another important characteristic of AAV is that it is an extremely stable and durable virus. This means it readily withstands the conditions used to inactivate adenoviruses (56°C–65°C for several hours), reducing the importance of chilling AAV. AAV can even be freeze-dried. Finally, AAV-infected cells are not resistant to co-infection.
[0010] There remains a need in the art for products and methods for treating muscular dystrophy, including but not limited to FSHD. This disclosure provides a U7 micronuclear RNA (U7 snRNA) approach for inhibiting DUX4 expression in muscle cells. [Prior art documents] [Non-patent literature]
[0011] [Non-Patent Document 1] Wallace et al.,Mol Ther Methods Clin Dev8,121-130(2018) [Overview of the project]
[0012] This disclosure provides products, methods, and uses for inhibiting DUX4 expression and for treating, improving, slowing the progression of, and / or preventing muscular dystrophy. In some embodiments, the muscular dystrophy is facioscapulohumeral dystrophy (FSHD).
[0013] This disclosure provides nucleic acids designed to inhibit DUX4 expression, viral vectors containing nucleic acids, compositions and kits containing nucleic acids and vectors, methods for using these products to inhibit and / or interfere with the expression of the DUX4 gene in cells, and methods for treating subjects suffering from muscular dystrophy.
[0014] This disclosure provides nucleic acids encoding U7 dual homeobox 4 (DUX4) antisense ribonucleic acid (asRNA), the nucleic acids comprising (a) a nucleotide sequence having at least 90% identity with the sequence shown in any one of sequence numbers 1 to 18, (b) a nucleotide sequence shown in any one of sequence numbers 1 to 18, or (c) a combination of (a) and / or (b).
[0015] This disclosure provides nucleic acids comprising a nucleotide sequence encoding a U7 double homeobox 4 (DUX4) antisense sequence that specifically hybridizes to a DUX4 target nucleotide sequence shown in any one of SEQ ID NOs: 19-36, or a combination of nucleotide sequences encoding a U7 double homeobox 4 (DUX4) antisense sequence that specifically hybridizes to a DUX4 target nucleotide sequence shown in any one of SEQ ID NOs: 19-36.
[0016] In some embodiments, the nucleic acids of the Disclosure are under the control of a promoter and therefore include a promoter nucleotide sequence. In some embodiments, the promoter is one of the following: U6 promoter, U7 promoter, tRNA promoter, H1 promoter, minimal CMV promoter, T7 promoter, EF1-alpha promoter, minimal EF1-alpha promoter, or muscle-specific promoter. In some further embodiments, the muscle-specific promoter is the unc45b promoter, tMCK promoter, minimal MCK promoter, CK6 promoter, CK7 promoter, MHCK7 promoter, or CK1 promoter.
[0017] In some embodiments, the Disclosure includes nanoparticles, extracellular vesicles, exosomes, or vectors comprising any or a combination thereof of the nucleic acids of the Disclosure. In some embodiments, one or more nucleic acids are combined with a single nanoparticle, an extracellular vesicle, an exosome, or a vector. In some embodiments, the nanoparticles are liposomes or micelles.
[0018] In some embodiments, the Disclosure includes vectors comprising the nucleic acids of the Disclosure or combinations thereof. Embodiments of the Disclosure deliver the nucleic acids of the Disclosure herein using a vector (e.g., adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, equine-associated virus, alphavirus, poxvirus, herpesvirus, herpes simplex virus, poliovirus, Sindbisvirus, vaccinia virus, or synthetic virus, e.g., chimeric virus, mosaic virus, or pseudotyped virus, and / or viral vectors such as viruses containing foreign proteins, synthetic polymers, nanoparticles, or small molecules). Thus, in some embodiments, the Disclosure provides vectors comprising any one or combinations thereof of the nucleic acids of the Disclosure. In some embodiments, the vector is adeno-associated virus (AAV) or a viral vector. In some embodiments, the AAV lacks rep and cap genes. In some embodiments, the AAV is recombinant AAV (rAAV) or self-complementary recombinant AAV (scAAV). In some aspects, rAAV is rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, rAAV11, rAAV12, rAAV13, rAAV-anc80, rAAVrh.74, rAAVrh.8, rAAVrh.10, or rAAV-B1. In some aspects, AAV is rAAV-9.
[0019] This disclosure provides compositions comprising (a) nucleic acids or combinations of such nucleic acids as described herein, (b) nanoparticles, extracellular vesicles, exosomes, or vectors as described herein, (c) viral vectors as described herein, or (d) compositions as described herein. In some embodiments, the compositions include a pharmaceutically acceptable carrier.
[0020] This disclosure provides a method for inhibiting and / or interfering with the expression of the dual homeobox 4 (DUX4) gene in cells, comprising contacting cells with (a) nucleic acids or combinations thereof of the Disclosure, (b) nanoparticles, extracellular vesicles, exosomes, or vectors of the Disclosure, (c) viral vectors of the Disclosure, or (d) compositions of the Disclosure. In some embodiments, the cells are in a subject. In some embodiments, the subject is a human subject.
[0021] This disclosure provides a method for treating a subject having muscular dystrophy, comprising administering to the subject an effective amount of (a) nucleic acids or combinations thereof of the Disclosed, (b) nanoparticles, extracellular vesicles, exosomes, or vectors of the Disclosed, (c) viral vectors of the Disclosed, or (d) compositions of the Disclosed. In some embodiments, the muscular dystrophy is facioscapulohumeral muscular dystrophy (FSHD).
[0022] This disclosure provides a method for treating a subject having cancer, comprising administering to the subject an effective amount of (a) nucleic acids or combinations thereof of the Disclosure, (b) nanoparticles, extracellular vesicles, exosomes, or vectors of the Disclosure, (c) viral vectors of the Disclosure, or (d) compositions of the Disclosure. In some embodiments, the cancer is a sarcoma.
[0023] This disclosure provides the use of (a) nucleic acids or combinations thereof, (b) nanoparticles, extracellular vesicles, exosomes, or vectors thereof, (c) viral vectors thereof, or (d) compositions thereof, for the preparation of pharmaceuticals for inhibiting the expression of the dual homeobox 4 (DUX4) gene in cells. In some embodiments, cells are present in the subject. In some embodiments, the subject is a human subject.
[0024] This disclosure provides the use of (a) nucleic acids or combinations thereof, (b) nanoparticles, extracellular vesicles, exosomes, or vectors thereof, (c) viral vectors thereof, or (d) compositions thereof, for inhibiting the expression of the dual homeobox 4 (DUX4) gene in cells. In some embodiments, the cells are in the subject. In some embodiments, the subject is a human subject.
[0025] This disclosure provides the use of (a) nucleic acids or combinations thereof, (b) nanoparticles, extracellular vesicles, exosomes, or vectors thereof, (c) viral vectors thereof, or (d) compositions thereof, for the preparation of pharmaceuticals for the treatment or improvement of muscular dystrophy.
[0026] This disclosure provides the use of (a) nucleic acids or combinations thereof, (b) nanoparticles, extracellular vesicles, exosomes, or vectors thereof, (c) viral vectors thereof, or (d) compositions thereof, for the treatment or improvement of muscular dystrophy. In some embodiments, muscular dystrophy is FSHD.
[0027] This disclosure provides the use of (a) nucleic acids or combinations thereof, (b) nanoparticles, extracellular vesicles, exosomes, or vectors thereof, (c) viral vectors thereof, or (d) compositions thereof, for the preparation of pharmaceuticals for treating or improving cancer. In some embodiments, cancer is sarcoma.
[0028] This disclosure provides the use of (a) nucleic acids or combinations thereof, (b) nanoparticles, extracellular vesicles, exosomes, or vectors thereof, (c) viral vectors thereof, or (d) compositions thereof, for the treatment or improvement of cancer. In some embodiments, cancer is sarcoma.
[0029] This disclosure also provides methods and uses for formulating nucleic acids, nanoparticles, extracellular vesicles, exosomes, vectors, viral vectors, compositions, or pharmaceuticals of this disclosure for intramuscular injection, transdermal delivery, or infusion into the bloodstream.
[0030] Further aspects and advantages of the present disclosure will be apparent to those skilled in the art from a review of the following detailed description, which is provided in conjunction with the drawings. However, the detailed description (including the drawings and specific embodiments) illustrates embodiments of the subject matter disclosed, but is given only as an example, so that various changes and modifications within the spirit and scope of the present disclosure will be apparent to those skilled in the art from this detailed description. [Brief explanation of the drawing]
[0031] [Figure 1]Figures 1A–D show that U7-asDUX4 snRNA protects HEK293 cells from DUX4-mediated death. Figure 1A shows the U7-snRNA structure consisting of a stabilizing hairpin-loop, an Sm-binding region, and an antisense sequence complementary to the target site on the DUX4 premRNA (see Table 1 for sequences). Figure 1B is a schematic diagram of 18 U7-asDUX4 constructs targeting different parts of the DUX4 mRNA. ATG indicates the start codon. Exon 1 (Ex1) contains the entire DUX4 open reading frame, while Ex2 and Ex3 contain the 3' untranslated region (3'UTR). *P≦0.05, **P≦0.01, ANOVA. N=3 independent experiments performed in triple assay. Figure 1C shows the results of a caspase-3 / 7 assay for apoptosis. All DUX4-targeted U7-asDUX4 snRNA constructs significantly reduced caspase-3 / 7 activity, with the exception of cells treated with sequence 6. Of the 18 constructs tested, 14 reduced caspase-3 / 7 activity by more than 50% (with exceptions being 1, 2, 6, and 18). Cells with the lowest relatively low caspase-3 / 7 activity (normalized to activity in cells transfected with DUX4 alone) were treated with U7-asDUX4-3 (34±12), U7-asDUX4-4 (26±7), U7-asDUX4-7 (36±8), U7-asDUX4-11 (30±3), and U7-asDUX4-16 (33±6). Figure 1D shows that cell viability was significantly increased in all U7-asDUX4-treated cells compared to cells transfected with DUX4 alone, with U7-asDUX4-7 (94.8%±4.9%), U7-asDUX4-8 (84.7%±3.8%), and U7-asDUX4-4 (78.5%±8.4%) showing the highest percentage of viable cells (P<0.01, ANOVA, N=3 independent experiments). [Figure 2]Figures 2A-H show that U7-asDUX4 snRNA significantly reduced the overexpression of DUX4 mRNA in transfected HEK293 cells. RNAscope assay: The DUX4 mRNA signal appeared as brown punctate dots in transfected cells (Figures 2A-D). Figure 2A shows the high DUX4 signal detected in HEK293 cells co-transfected with CMV.DUX4 and DUX4-untargeted U7 control plasmids. Decrease in brown DUX4 signal after co-transfection of HEK293 cells with CMV.DUX4 and U7-asDUX4-4 (Figure 2B), U7-asDUX4-7 (Figure 2C), and U7-asDUX4-8 (Figure 2D) plasmids. Figure 2E shows the background signal from the DUX4 probe in an untransfected HEK293 cell line. Figure 2F shows that the housekeeping gene PPIB was detected in all HEK293 cells and served as a positive control for the assay. Figure 2G shows that the bacterial gene dapB probe was used as a negative control for the RNAscope assay. Figure 2H shows that RNAscope quantification significantly reduced the DUX4-positive signal in DUX4-transfected cells co-expressing U7-asDUX4snRNA4, 7, and 8. 40× objective lens. Scale bar, 50 microns. Quantification was performed as described in reference 30 (see last citation in disclosure). Two representative microscopic fields were counted from three independent experiments, with each point representing a quantification of one field. **P<0.01, ANOVA. [Figure 3]Figures 3A–E show that U7-asDUX4 snRNA reduces DUX4 protein production in transfected HEK293 cells. Figure 3A shows a schematic diagram of a full-length DUX4 expression construct containing the C-terminal V5 epitope tag. The 42 bp DNA sequence encoding the 14-amino acid V5 tag disrupted the U7-asDUX4-4 target site. The black bar in exon 1 (Ex1) represents DNA-binding homeodomains 1 and 2 (HOX1 and HOX2), but is not scaled. Introns 1 and 2 are shown as the ∨ symbol. Figure 3B shows anti-V5 immunofluorescence staining of HEK293 cells co-transfected with CMV.DUX4-V5, where the DUX4-V5 signal appears as red fluorescence. Blue DAPI staining (4',6-diamidino-2-phenylindole) shows the HEK293 nucleus. The U7-asDUX4-7 and U7-asDUX4-8 constructs reduced DUX4-V5 protein staining compared to cells treated with untargeted U7-snRNA. The U7-asDUX4-4 sequence was functional in other assays but did not reduce DUX4-V5 protein expression due to disruption of its binding site by the V5 tag, as shown in Figure 3A. 40× objective lens. Scale bar, 50 microns. Figure 3C shows the Myc-DUX4-fl construct used in the Western blot assay and the possible mechanism of DUX4 inhibition by lead U7-asDUX4 targeting of DUX4 (discussed in context). DUX4-s is a potentially non-toxic isoform of DUX4 lacking the C-terminal transactivation domain. Figure 3D shows that the Western blot results demonstrated reduced DUX4 protein in U7-asDUX4-treated cells compared to those transfected with untargeted U7-snRNA. Two bands, 52kDa and 60kDa, appeared on Western blotting after using an anti-Myc antibody against HEK293 cell extracts transfected with CMV.myc-DUX4. The 60kDa protein band was detected in untransfected cells and shifted approximately by the size of the endogenous Myc protein.Consistent with previously observed immunofluorescence, cell death, and RNAscope results, U7-asDUX4 snRNA reduced transfected DUX4 expression compared to untargeted controls. Western blotting was performed three times using protein extracts from three independent experiments (raw blots shown in Figure 6). Tubulin was used as a normalizer. Figure 3E shows the quantification of the Western blots in Figure 3D. DUX4 protein signal intensity was significantly reduced in cells treated with U7-asDUX4-4 (87.4% ± 9.8) and U7-asDUX4-8 (84.7% ± 13.5) compared to untargeted controls. U7-asDUX4-5 and -7 target similar splice junction sites, while U7-asDUX4-6 targets the intron 1SD site. These three constructs were tested to determine which of them could induce DUX4-s production by altering the correct splicing of full-length DUX4 mRNA. The DUX4 short protein band (22kDa) was not detected using Western blot assay. **P≦0.01, ANOVA, N=3 independent experiments, each experiment normalized to its respective non-target control and set to 100% DUX4 expression. [Figure 4]Figures 4A-I show that the U7-asDUX4 construct reduces endogenous DUX4 and DUX4-related biomarkers in myotubes derived from FSHD patients. Figure 4A shows that FSHD15A myotubes exhibited a higher level of DUX4 mRNA signaling compared to cells treated with U7-asDUX4. The arrows in the panel of Figure 4A indicate that DUX4-positive examples represent a brown signal. DUX4 expression in FSHD15A myotubes was reduced or absent in 15A cells transfected with U7-asDUX4-4 (Figure 4B), U7-asDUX4-7 (Figure 4C), and U7-asDUX4-8 (Figure 4D). Figure 4E shows the presence or absence of a very weak signal in unaffected 15V myotubes, which served as a negative control for RNAscope staining using the DUX4 probe. Figure 4F shows 15A myotubes stained with the housekeeping gene PPIB-positive control for the RNAscope assay. Figure 1G shows 15A myotubes stained with the bacterial dapB gene probe, which served as a negative control for the assay. 100× objective lens. Scale bar, 20 microns. Figure 1H shows the quantification of the DUX4 RNAscope signal, performed as described in reference 30. Three to four representative microscopic fields were counted from three independent experiments, with each point representing the quantification of one field. **P<0.01, ANOVA.** The DUX4 signal was absent or very low in unaffected 15V cells and similarly in affected 15A cells transfected with the lead U7-asDUX4 snRNA plasmid, compared to untreated affected 15A samples. **P≦0.01, ANOVA.** Figure 4I shows the knockdown of the DUX4 activation biomarker by the U7-asDUX4 sequence. The plot shows significant reductions in ZSCAN4, PRAMEF12, MBD3L2, and TRIM43 in U7-asDUX4-treated FSHD15A myotubes compared to controls transfected with untargeted snRNA. N=4 independent experiments performed in triple or, in some cases, double measurements. **P≦0.01, ANOVA. [Figure 5A-1]Figures 5A-C show the splice sites and splice enhancer / silencer sites predicted for DUX4 premRNA using predictions from the Human Splice Finder 3.1 Tool. Figure 5A shows the U7-asDUX4 binding site locations that overlap with the predicted splice motifs (Figures 5B-C). [Figure 5A-2] Same as above. [Figure 5B-1] Same as above. [Figure 5B-2] Same as above. [Figure 5B-1] Same as above. [Figure 5B-2] Same as above. [Figure 5C-1] Same as above. [Figure 5C-2] Same as above. [Figure 6A] Figures 6A-6C show raw Western blots 1 (Figure 6A), 2 (Figure 6B), and 3 (Figure 6C). [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 7] This shows that DUX4-s was not detected by nested RT-PCR. cDNA synthesis was primed using the previously reported oligo-dT adapter primer (Giesige et al., JCI Insight 2018;3(22):e123538). 3 μl of the cDNA product was used as a template for the first PCR reaction, and then this product was diluted 1 / 10 in the second PCR round. The expected 569 bp band for DUX4-s was observed only in the positive control (DUX4-s transfected cells) and was not present in the other samples. This experiment was repeated at least four times in DUX4-transfected HEK293 and 15A human FSHD myotubes. DNA ladder, TrackIt 1Kb, and DNA ladder. 1.5% agarose gel.
[0032] [Table 1] [Figure 8]This study demonstrates that human 15V FSHD myoblasts can be efficiently transfected with the CMV.GFP plasmid. This experiment was conducted to confirm that the effectiveness of DUX4 inhibition via U7-snRNA plasmid transfection can be tested using human myoblasts. [Figure 9] Figure 9 shows the development of an RNAscope probe for in vivo use. The RNAscope probe was designed to detect DUX4 and five DUX4-activating biomarkers: MBD3L2, PRAMEF12, LEUTX, ZSCAN4, and TRIM43. The upper panel of Figure 9 shows the in vitro optimization of the probe using DUX4 plasmid-transfected HEK293 (brown stained). The lower panel shows the co-localization of DUX4 and TRIM43 signals in serial sections from FSHD patient muscle biopsies. Arrows indicate signals. Letters a, b, and c are used to help align the serial sections. A clear signal from the DUX4 probe was identified in 11 out of 20 samples, and TRIM43 was identified in 13 out of 20 samples. Two samples had TRIM43 without a clear DUX4 signal, while seven samples showed neither DUX4 nor TRIM43 signal. These results demonstrate that DUX4 is not uniformly found in all myonuclei from FSHD patient biopsies. These results also demonstrate that RNAscope can be used to detect DUX4 mRNA in vivo in patient samples, which can be used as an outcome measure for clinical use. [Modes for carrying out the invention]
[0033] This disclosure provides novel strategies to achieve post-transcriptional DUX4 gene expression by suppressing or inhibiting DUX4 protein production, since the expression of double homeobox protein 4 (DUX4) in muscle is known to cause muscular dystrophy, including but not limited to facioscapulohumeral muscular dystrophy (FSHD). Accordingly, in some embodiments, the products and methods described herein can be used in treating, improving, delaying the progression of, and / or preventing FSHD.
[0034] The DUX4 gene encodes a protein of approximately 45 kDA (see UniProtKB-Q9UBX2(DUX4_HUMAN)). Derepression of the DUX4 gene is involved in the development of FSHD. Derepression can occur through two known mechanisms: D4Z4 repeat contraction, or mutations in the chromatin-altering genes SMCHD1 or DNMT3B. In the former, the D4Z4 sequence consists of 11–100 repeats in unaffected subjects, but is reduced to 1–10 repeats in FSHD1 patients (PubMed:19320656). Both conditions can lead to DNA hypomethylation at chromosome 4q35, thereby creating a chromosomal environment that allows for DUX4 expression.
[0035] DUX4 is located in the D4Z4 macrosatellite repeat, which is epigenetically repressed in somatic cell tissues. D4Z4 chromatin relaxation in FSHD1 leads to inefficient epigenetic repression of DUX4 and diversified patterns of DUX4 protein expression in a subset of skeletal muscle nuclei. Ectopic expression of DUX4 in skeletal muscle activates the expression of stem cell and germ cell genes, and when overexpressed in somatic cells, DUX4 can ultimately lead to cell death.
[0036] Each D4Z4 repeat unit has an open reading frame (named DUX4) encoding two homeoboxes, and the repeat sequence and ORF are conserved in other mammals. The encoded protein has been reported to function as a transcriptional activator of many genes, including ZSCAN4, PRAMEF12, TRIM43, and several others that are thought to be FSHD disease biomarkers, including MBD3L2 (PMID:24861551). Macrosatellite repeat contraction causes autosomal dominant FSHD. Alternative splicing results in multiple transcriptional variants.
[0037] In some embodiments of this disclosure, DUX4 nucleic acids and proteins are provided. In some embodiments, the nucleic acid encoding human DUX4 is represented by the nucleotide sequence shown in SEQ ID NO: 37. In some embodiments, the amino acid sequence of human DUX4 is represented by the amino acid sequence shown in SEQ ID NO: 38. In various embodiments, the methods of this disclosure also target isoforms and variants of the nucleotide sequence shown in SEQ ID NO: 37. In some embodiments, the variants include 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, and 70% identity with the nucleotide sequence shown in SEQ ID NO: 37. In some embodiments, the methods of the present disclosure target isoforms and variants of nucleic acids comprising a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 38. In some embodiments, the variants include 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, and 70% identity with the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 38.
[0038] [Table 2]
[0039] Currently, there is no treatment for FSHD, and despite its relatively high prevalence among muscular dystrophy, few studies on FSHD-targeted translation have been published. While several candidate genes for FSHD have been identified, many recent studies support the idea that the primary contributing factor to FSHD development is the pro-apoptotic DUX4 gene, which encodes a transcription factor. Therefore, in very simple terms, DUX4 overexpression is the major pathogenic injury underlying FSHD (Chen et al., (2016) Mol Ther 24, 1405-1411, Ansseau et al. (2017) Genes (Basel) 8, Lek et al. (2020) Sci Transl Med 12, Himeda et al. (2016) Mol Ther 24, 527-535, DeSimone et al. (2019) Sci Adv 5, 12, Lim et al. (2020) Proc Natl Acad Sci USA 117, 16509-16515, Wallace et al. (2018), Rojas et al. (2020) J Pharmacol Exp Ther. Sep; 374(3): 489-498).
[0040] In some embodiments, this disclosure provides antisense RNA (asRNA), also known as antisense transcript, natural antisense transcript, or antisense oligonucleotide. Antisense RNA is a single-stranded RNA that is complementary to the protein-coding messenger RNA (mRNA) with which it hybridizes, thereby blocking its translation into a protein. The primary function of asRNA is to regulate gene expression. Antisense RNA can also be produced synthetically as described herein and used in downregulating DUX4 expression.
[0041] This disclosure provides novel constructs and methods for achieving DUX4 knockdown or silencing by using U7 antisense (as) DUX4 snRNA. U7-as snRNA is transcribed in the nucleus, then exported to the cytoplasm, where it is assembled with Sm and Lsm proteins. The assembled U7-snRNP may remain in the cytoplasm or be imported back into the nucleus. In the nucleus, they are involved in splicing mechanisms, while in the cytoplasm, they are involved in P bodies and typically function in mRNA transposition (Liu et al. (2007). PNAS104(28), 11655-11659). Similarly, mRNA can be detected in both the nucleus and cytoplasm; they are transcribed and matured in the nucleus and then transported to the cytoplasm for translation.
[0042] In some embodiments, this disclosure provides gene therapy approaches for treating FSHD by downregulating or inhibiting the expression of the toxic DUX4 gene in muscle. The full-length DUX4 gene product causes cell death and myotoxicity, and therefore the FSHD therapies described herein are designed to inhibit full-length DUX4 expression. In some embodiments described herein, DUX4 inhibition is achieved using a U7-snRNA antisense expression cassette (referred to as U7-asDUX4). These non-coding RNAs are designed to inhibit the production or maturation of full-length DUX4 premRNA by masking the DUX4 start codon, splice site, or polyadenylation signal. The U7-asDUX4 construct has three main features: a stable hairpin structure at one end, a binding site to the Sm protein, and an antisense region that can be modified to target any gene of interest, e.g., DUX4.
[0043] Several constructs identified herein target the exon 1 / intron 1 junction (i.e., U7-asDUX4-4 and -7) or the DUX4 poly-A signaling pathway (PAS) (i.e., U7-asDUX4-8). The use of antisense sequences that bind to DUX4PAS has already been demonstrated using chemically synthesized ASOs and has been shown to reduce DUX4 and DUX4 activation biomarkers in vitro and in vivo (Vanderplanck et al. (2011) PLoS One 6, e26820, Marsollier et al. (2016) Hum Mol Genet 25, 1468-1478, Chen, et al. (2016) Mol Ther 24, 1405-1411, Ansseau et al. (2017) Genes (Basel) 8), but targeting the splice junction is a novel approach. The U7-asDUX4 sequence described herein is unique and novel, incorporating additional sequences that recruit Sm and Lsm proteins, and is expressed in vivo from a promoter, thus differing from ASOs. Polyadenylation is a critical process required to stabilize nascent mRNA and regulate its passage through the nuclear pore to the cytoplasm for translation. While chemically synthesized DNA-based ASOs may act by forming DNA:RNA hybrids and activating RNAse H against target transcripts, it is also possible that a publicly available ASO sequence designed to base-pair with DUX4PAS may act by masking the signal and preventing polyadenylation, thereby potentially leading to DUX4 mRNA destabilization.
[0044] In some embodiments, the Disclosure provides a nucleic acid (U7-asDUX4) comprising a nucleotide sequence encoding a U7snRNA that targets DUX4 and inhibits DUX4 expression. The Disclosure comprises various nucleic acids comprising, essentially consisting of, or comprising various nucleotide sequences described herein. In some embodiments, the nucleic acid comprises a nucleotide sequence. In some embodiments, the nucleic acid consists essentially of a nucleotide sequence. In some embodiments, the nucleic acid consists of a nucleotide sequence.
[0045] Therefore, in some embodiments, the disclosure includes nucleic acids comprising polynucleotides encoding inhibitory RNA to prevent and inhibit the expression of the DUX4 gene. The inhibitory RNA comprises an antisense sequence that inhibits the expression of DUX4. The sequences shown in SEQ ID NOs: 1-18 are DNA sequences encoding U7snRNA that prevent and inhibit the expression of the DUX4 gene.
[0046] In some embodiments, the term “U7-asDUX4” is used interchangeably herein to mean the nucleotide sequence shown in any one of SEQ ID NOs: 1 to 18. In some other embodiments, the disclosure includes nucleic acids comprising a DUX4 antisense, e.g., a polynucleotide encoding U7-asDUX4, which targets a DUX4 sequence comprising the nucleotide sequence shown in any one of SEQ ID NOs: 19 to 36.
[0047] In some embodiments, the term "U7-asDUX4" is used interchangeably herein to mean a nucleotide sequence encoding a U7DUX4 antisense sequence that specifically hybridizes to a double homeobox 4 (DUX4) target nucleotide sequence shown in any one of SEQ ID NOs: 19-36.
[0048] Accordingly, in some embodiments, the Disclosure includes (1) a nucleic acid comprising any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 18, or a variant thereof having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with any one of the sequences shown in SEQ ID NOs: 1 to 18, and (2) a nucleic acid comprising a nucleotide sequence encoding an snRNA that targets any one of the nucleotide sequences shown in SEQ ID NOs: 19 to 36.
[0049] In some embodiments, the Disclosure includes nucleic acids comprising a nucleotide sequence comprising any one of the sequences shown in SEQ ID NOs: 1 to 18, under the control of the U7 promoter, or a variant thereof having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with any one of the sequences shown in SEQ ID NOs: 1 to 18. In some embodiments, the Disclosure includes nucleic acids comprising any one of the nucleotide sequences shown in SEQ ID NOs: 1 to 18, under the control of another promoter, which includes but is not limited to a muscle-specific promoter.
[0050] Accordingly, in some embodiments, the disclosure includes a nucleotide sequence encoding an snRNA that binds to any one of the target sequences shown in SEQ ID NOs: 19-36 under the control of the U7 promoter. In some embodiments, the disclosure includes a nucleic acid comprising a nucleotide sequence that binds to any one of the target sequences shown in SEQ ID NOs: 19-36 under the control of another promoter, which includes but is not limited to a muscle-specific promoter.
[0051] The exemplary nucleotide sequences used for DUX4 snRNA targeting described herein include, but are not limited to, those specified in Table 1 below. The various characteristics of these nucleotide sequences are shown in Table 2 below.
[0052] [Table 3-1]
[0053] [Table 3-2]
[0054] [Table 4-1]
[0055] [Table 4-2]
[0056] The DNA nucleotide sequences listed in Tables 1 and 2 above either (1) encode an RNA antisense sequence for targeting DUX4, or (2) are target sequence sites in DUX4snRNA.
[0057] In some embodiments, the disclosure provides snRNAs or U-RNAs that inhibit or interfere with the expression of the DUX4 gene. In some embodiments, the snRNAs are driven by or under the control of a human or mouse U7 promoter, i.e., U7snRNA. In some embodiments, the snRNAs are under the control of any other promoter, including, but not limited to, a tissue-specific promoter or a muscle-specific promoter.
[0058] In some embodiments, the products and methods of this disclosure include nucleic acids encoding micronuclear ribonucleic acid (snRNA), also commonly referred to as U-RNA, to downregulate or inhibit DUX4 expression. snRNA is a class of small RNA molecules found in the splicing speckles of the cell nucleus and in the Cajal body of eukaryotic cells. Micronuclear RNA is associated with a specific set of proteins, and the complex is called a micronuclear ribonucleoprotein (snRNP, often pronounced "snrp"). Each snRNP particle consists of an snRNA component and several snRNP-specific proteins (including Sm proteins, a family of nucleoproteins). Together with their associated proteins, snRNAs form ribonucleoprotein complexes (snRNPs) that bind to specific sequences on premRNA substrates. These are transcribed by either RNA polymerase II or RNA polymerase III. snRNAs are often classified into two classes based on both common sequence features and associated protein factors such as RNA-binding LSm proteins. The first class, known as the Sm class snRNAs, consists of U1, U2, U4, U4atac, U5, U7, U11, and U12. The Sm class snRNAs are transcribed by RNA polymerase II. The second class, known as the Lsm class snRNAs, consists of U6 and U6atac. The Lsm class snRNAs are transcribed by RNA polymerase III and, in contrast to the Sm class snRNAs, never leave the nucleus. In some aspects, this disclosure includes the production and administration of an AAV vector containing U7snRNA for the delivery of a DUX4 antisense sequence.
[0059] In some embodiments, the present disclosure describes the use of U7snRNA molecules to inhibit, knock down, or interfere with gene expression. U7snRNA is normally involved in histone premRNA 3' end processing, but in some embodiments, it is converted into a general-purpose tool for splicing regulation or as an antisense RNA that is continuously expressed in cells (Goyenvalle et al., Science 306 (5702): 1796-9 (2004)). By replacing the wild-type U7Sm binding site with a consensus sequence derived from spliceosome snRNA, the resulting RNA is assembled with the seven Sm proteins found in spliceosome snRNA (Figure 7). As a result, this U7Sm OPT RNA accumulates more efficiently in the nucleoplasm and no longer mediates histone premRNA cleavage, but can still bind to histone premRNA and act as a competitive inhibitor of wild-type U7snRNP. By further replacing the histone downstream element-binding sequence with one complementary to a specific target in the splicing substrate, it is possible to create U7 snRNAs that can modulate specific splicing events. The advantage of using U7 derivatives is that the antisense sequence is embedded in the micronuclear ribonucleoprotein (snRNP) complex. Furthermore, when embedded in gene therapy vectors, these small RNAs can be permanently expressed in target cells after a single injection [Gorman et al., Proc Natl Acad Sci.28;95(9):4929-34(1998), Goyenvalle et al., Science.3;306(5702):1796-9(2004), Levy et al., Eur.J.Hum.Genet.18(9):969-70(2010), Wein et al., Hum.Mutat.31(2):136-42,(2010), Wein et al., Nat.Med.20(9):992-1000(2014)].The use of U7 to alter CUG repeat expression has been tested in vitro in DM1 patient cell lines [Francois et al., Nat. Struct. Mol. Biol. 18(1):85-7 (2011)], and U7 RNA targeting CUG repeats has been shown to result in reduced levels of DUX4-associated lesions and modification of abnormal splicing patterns. However, this approach is lentivirus-based and has never been pursued further in vivo. The potential of the U7 snRNA system in neuromuscular disorders using the AAV approach has been investigated in vivo (AAV.U7) [Gorman et al., Proc Natl Acad Sci.28;95(9):4929-34(1998), Goyenvalle et al., Science.3;306(5702):1796-9(2004), Levy et al., Eur.J.Hum.Genet.18(9):969-70(2010), Wein et al., Hum.Mutat.31(2):136-42(2010), Wein et al., Nat.Med.20(9):992-1000(2014)].
[0060] U7 snRNAs are typically involved in histone premRNA 3'-terminal processing, but they are also used as versatile tools for splicing regulation or as antisense RNAs for continuous expression within cells. One advantage of using U7 derivatives is that the antisense sequence is embedded in the micronuclear-ribonucleoprotein (snRNP) complex. Furthermore, when embedded in gene therapy vectors, these small RNAs can be permanently expressed in target cells after a single injection.
[0061] In some embodiments, the Disclosure includes nanoparticles, extracellular vesicles, exosomes, or vectors comprising any of the nucleic acids of the Disclosure, or any combination thereof. In some embodiments, one or more nucleic acids are combined into a single nanoparticle, an extracellular vesicle, an exosome, or a vector. In some embodiments, the nanoparticles are liposomes or micelles.
[0062] In some embodiments, the Disclosure includes vectors comprising any of the nucleic acids described herein, or any combination thereof. Embodiments of the Disclosure utilize a vector (e.g., a viral vector such as adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, equine-associated virus, alphavirus, poxvirus, herpesvirus, herpes simplex virus, poliovirus, Sindbisvirus, vaccinia virus, or synthetic virus, such as a chimeric virus, mosaic virus, or pseudotyped virus, and / or a virus containing foreign proteins, synthetic polymers, nanoparticles, or small molecules) to deliver the nucleic acids disclosed herein.
[0063] In some embodiments, the Disclosure utilizes a vector (e.g., a viral vector such as adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, equine-associated virus, alphavirus, poxvirus, herpesvirus, herpes simplex virus, poliovirus, Sindbisvirus, vaccinia virus, or synthetic virus, such as a chimeric virus, mosaic virus, or pseudotyped virus, and / or a virus containing foreign proteins, synthetic polymers, nanoparticles, or small molecules) to deliver the nucleic acids or combinations of nucleic acids disclosed herein.
[0064] In some embodiments, the vector is an AAV vector. In some embodiments, the vector is a single-stranded AAV vector. In some embodiments, the AAV is recombinant AAV (rAAV). In some embodiments, the rAAV lacks rep and cap genes. In some embodiments, the rAAV is self-complementary (sc)AAV.
[0065] Therefore, in some embodiments, viral vectors include AAV1 (i.e., AAV containing AAV1 reverse terminal Repeat (ITR) and AAV1 capsid protein), AAV2 (i.e., AAV containing AAV2ITR and AAV2 capsid protein), AAV3 (i.e., AAV containing AAV3ITR and AAV3 capsid protein), AAV4 (i.e., AAV containing AAV4ITR and AAV4 capsid protein), AAV5 (i.e., AAV containing AAV5ITR and AAV5 capsid protein), AAV6 (i.e., AAV6ITR and AAV6 capsid protein), AAV7 (i.e., AAV7ITR and AAV7 capsid protein), AAV8 (i.e., AAV8ITR and AAV8 capsid protein), AAV9 (i.e., AAV These include adeno-associated viruses (AAVs) such as AAV-anc80, AAVrh.74, AAVrh.8, AAVrh.10, or AAV-B1. (i.e., AAV containing AAVrh.74 ITR and AAVrh.74 capsid protein)
[0066] Accordingly, some embodiments of this disclosure include a nucleic acid-based rAAV genome comprising a nucleotide sequence having at least about 90% sequence identity with the nucleotide sequence shown in any of SEQ ID NOs: 1 to 18, or a variant thereof. In addition, some embodiments of this disclosure include a nucleic acid-based rAAV genome comprising a nucleotide sequence binding to a target sequence shown in any of SEQ ID NOs: 19 to 36, as disclosed in the detailed description herein.
[0067] AAV is a replication-deficient parvovirus whose single-stranded DNA genome is approximately 4.7 kb long and contains 145 nucleotides in an inverted terminal repeat (ITR). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of AAV serotypes are known. For example, the complete genome of AAV1 is provided under GenBank accession number NC_002077, and the complete genome of AAV2 is provided under GenBank accession number NC_001401 and Srivastava et al. The complete genome of AAV3 is available in al., J. Virol., 45:555-564 (1983), the complete genome of AAV4 is available in GenBank accession number NC_1829, the complete genome of AAV4 is available in GenBank accession number NC_001829, the genome of AAV5 is available in GenBank accession number AF085716, the complete genome of AAV6 is available in GenBank accession number NC_001862, at least portions of the genomes of AAV7 and AAV8 are available in GenBank accession numbers AX753246 and AX753249, respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 related to AAV8), and the genome of AAV9 is available in Gao et al. The AAV10 genome is available in al., J. Virol., 78:6381-6388 (2004), the AAV11 genome in Mol. Ther., 13(1):67-76 (2006), the AAV11 genome in Virology, 330(2):375-383 (2004), the AAV12 genome in J Virol. 2008 Feb;82(3):1399-406, and the AAV13 genome in J Virol 2008;82:8911. Cis-acting sequences that direct viral DNA replication (rep), capsid formation / packaging, and integration into host cell chromosomes are contained within the AAV ITR. Three AAV promoters (named p5, p19, and p40 based on their relative map locations) drive the expression of two AAV internal open reading frames that encode the rep and cap genes.Two rep promoters (p5 and p19), linked to differential splicing of a single AAV intron (nucleotide positions 2107 and 2227), result in the production of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. These rep proteins possess multiple enzymatic properties that ultimately contribute to the replication of the viral genome. The cap gene, expressed from the p40 promoter, encodes three capsid proteins: VP1, VP2, and VP3. Alternative splicing and non-consensus translation initiation sites contribute to the production of these three related capsid proteins. A single-consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992).
[0068] AAV possesses unique characteristics that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is non-cellular, and natural infection in humans and other animals is asymptomatic. Furthermore, AAV can infect many mammalian cells, giving it the potential to target many different tissues in vivo. In addition, AAV can transduce slow-dividing and non-dividing cells and persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in a plasmid, enabling the construction of recombinant genomes. Furthermore, because the signals directing AAV replication, genomic capsid formation, and integration are contained within the ITR of the AAV genome, some or all of the approximately 4.7kb of genome inside (rep-cap, encoding replication and structural capsid proteins) can be replaced with foreign DNA. The rep and cap proteins can be supplied trans. Another important characteristic of AAV is that it is an extremely stable and robust virus. This makes AAV easily resistant to the conditions used to inactivate adenoviruses (56°C to 65°C for several hours), reducing the importance of chilling AAV. AAV can be freeze-dried, and AAV-infected cells are not resistant to reinfection.
[0069] In some embodiments, a DNA plasmid of the Disclosure is provided, comprising the rAAV genome of the Disclosure. The DNA plasmid is transferred to a cell tolerant of infection with an AAV helper virus (e.g., adenovirus, E1 deletion adenovirus, or herpesvirus) for assembly of the rAAV genome into infectious viral particles. Techniques for producing rAAV particles that provide a cell with the AAV genome to be packaged, rep and cap genes, and helper virus function are standard in the art. The production of rAAV requires the following components present in a single cell (indicated herein as a packaging cell): the rAAV genome, AAV rep and cap genes separate from (i.e., not present in) the rAAV genome, and helper virus function. The AAV rep gene may be from any AAV serotype from which the recombinant virus can originate, and may be from AAV serotypes different from the rAAV genome ITR, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV-anc80, AAVrh.74, AAVrh.8, AAVrh.10, and AAV-B1. In some embodiments, the AAV DNA in the rAAV genome is from any AAV serotype, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV-anc80, AAVrh.74, AAVrh.8, AAVrh.10, and AAV-B1, from which recombinant viruses can originate. Other types of rAAV variants, such as rAAVs with capsid variants, are also included in this disclosure. See, for example, Marsic et al., Molecular Therapy 22(11):1900-1909 (2014). As described above, nucleotide sequences of genomes of various AAV serotypes are known in the art. The use of congeneral components is specifically intended.The production of pseudotyped rAAV is disclosed, for example, in WO01 / 83692, which is incorporated herein by reference in its entirety.
[0070] In some embodiments, the recombinant AAV genome of this disclosure includes one or more AAV ITRs flanking a polynucleotide sequence, e.g., one or more antisense sequences that bind to a major exon-defining element within the premRNA. Thus, in some embodiments, the rAAV genome of this disclosure includes, for example, one or more AAV ITRs flanking a polynucleotide encoding one or more DUX4 antisense sequences. Commercial providers such as Ambion Inc. (Austin, TX), Darmacon Inc. (Lafayette, CO), InvivoGen (San Diego, CA), and Molecular Research Laboratories, LLC (Herndon, VA) construct custom inhibitory RNA molecules. In addition, commercially available kits are available to generate custom siRNA molecules, such as the SILENCER® siRNA construction kit (Ambion Inc., Austin, TX) or the psiRNA system (InvivoGen, San Diego, CA).
[0071] Accordingly, in some embodiments, the recombinant AAV genome of the present disclosure comprises one or more AAV ITRs adjacent to at least one DUX4-targeted polynucleotide construct. In some embodiments, the polynucleotide is an snRNA, a polynucleotide encoding an snRNA, or a polynucleotide encoding an snRNA designed to bind to a target sequence. In some embodiments, the polynucleotide encoding an snRNA is administered together with other polynucleotide constructs that target DUX4.
[0072] In various embodiments, promoters are used to enable tissue-specific expression. In some embodiments, snRNAs are expressed under a variety of promoters, including, but not limited to, the U6 promoter, U7 promoter, T7 promoter, tRNA promoter, H1 promoter, EF1-alpha promoter, minimal EF1-alpha promoter, unc45b promoter, CK1 promoter, CK6 promoter, CK7 promoter, miniCMV promoter, CMV promoter, muscle creatine kinase (MCK) promoter, alpha-myosin heavy chain enhancer- / MCK enhancer-promoter (MHCK7), tMCK promoter, minimal MCK promoter, or desmin. The AAV DNA in the rAAV genome may be from any AAV serotype, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAV-anc80, AAVrh.74, AAVrh.8, AAVrh.10, and AAV-B1, from which recombinant viruses can originate. As shown above, nucleotide sequences of genomes for various AAV serotypes are known in the art.
[0073] In some embodiments, the viral vector is a pseudotyped AAV containing an ITR from one AAV serotype and a capsid protein from a different AAV serotype. In some embodiments, the pseudotyped AAV is AAV2 / 9 (i.e., an AAV containing AAV2ITR and AAV9 capsid protein). In some embodiments, the pseudotyped AAV is AAV2 / 8 (i.e., an AAV containing AAV2ITR and AAV8 capsid protein). In some embodiments, the pseudotyped AAV is AAV2 / 1 (i.e., an AAV containing AAV2ITR and AAV1 capsid protein).
[0074] In some embodiments, the AAV contains recombinant capsid proteins, such as a capsid protein containing a chimera of one or more capsid proteins from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV-anc80, AAVrh74, AAVrh.8, or AAVrh.10, AAV10, AAV11, AAV12, AAV13, or AAV-B1. Other types of rAAV variants, e.g., rAAVs having capsid variants, are also intended. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). As shown above, nucleotide sequences of genomes of various AAV serotypes are known in the art.
[0075] In some embodiments, packaging cells are provided. Packaging cells are prepared to have a cell line that stably expresses all the components necessary for AAV particle production. Retroviral vectors are prepared by removing the retroviral gag, pol, and env genes. These are replaced by therapeutic genes. Packaging cells are essential for producing vector particles. Packaging cell lines provide all the viral proteins necessary for capsid production and virion maturation of the vector. Therefore, packaging cell lines are prepared so that they contain the gag, pol, and env genes. After inserting the desired genes into a retroviral DNA vector and maintaining a suitable packaging cell line, preparing the retroviral vector is now straightforward.
[0076] For example, a plasmid (or multiple plasmids) containing an rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separated from the rAAV genome, and selectable markers such as neomycin resistance genes is incorporated into the cell genome. The AAV genome is introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantage of this method is that cells are selectable and it is suitable for large-scale production of rAAV. Another example of a preferred method is to use adenovirus or baculovirus, rather than plasmid, to introduce the rAAV genome and / or rep and cap genes into packaging cells.
[0077] In some embodiments, the Disclosure includes compositions comprising any of the nucleic acids or vectors described herein in combination with a diluent, excipient, or buffer.
[0078] Therefore, in some embodiments, a method is provided for producing packaging cells that give rise to cell lines that stably express all the components necessary for AAV particle production. For example, a plasmid (or a group of plasmids) containing an rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separated from the rAAV genome, and a selectable marker such as a neomycin resistance gene is incorporated into the cell genome. The AAV genome has been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy et al., 1984, J. Biol. Chem., 259:4661-4666). Next, the packaging cell line is infected with a helper virus such as adenovirus. The advantage of this method is that the cells are selectable and it is suitable for large-scale production of rAAV. Another example of a preferred method is to use adenovirus or baculovirus instead of plasmid to introduce the rAAV genome and / or rep and cap genes into the packaging cells.
[0079] The general principles of rAAV production have been reviewed, for example, in Carter, 1992, Current Opinions in Biotechnology, 1533-539, and Muzyczka, 1992, Curr. Topics in Microbiol. and Immunol. 158:97-129). Various approaches have been proposed by Ratschin et al., Mol. Cell. Biol. 4:2072 (1984), Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984), Tratschin et al., Mo1. Cell. al., J. Virol., 62:1963 (1988), and Lebkowski et al., 1988 Mol. Cell. Biol., 7: 349 (1988), Samulski et al. al., J. Virol., 63:3822-3828 (1989), U.S. Patent No. 5,173,414, WO95 / 13365 and corresponding U.S. Patent No. 5,658,776, WO95 / 13392, WO96 / 17947, PCT / US98 / 18600, WO97 / 09441 (PCT / US96 / 14423), WO97 / 08298 (PCT / US96 / 13872), WO97 / 21825 (PCT / US96 / 20777), WO97 / 06243 (PCT / FR96 / 01064), WO99 / 11764, Perrin et al., Vaccine, 13:1244-1250 (1995), Paul et al. This is described in al., Human Gene Therapy, 4:609-615 (1993), Clark et al., Gene Therapy, 3:1124-1132 (1996), U.S. Patent Nos. 5,786,211, 5,871,982, and 6,258,595, and McCarty, Mol. Ther., 16(10):1648-1656 (2008). The aforementioned documents are incorporated herein by reference in their entirety, with particular emphasis on these parts of the documents relating to rAAV production. Various types of rAAV production and use are specifically contemplated and illustrated.Therefore, recombinant AAV (i.e., infectious capsidized rAAV particles) are provided herein. In some embodiments, the rAAV genome lacks AAV rep and cap genes, i.e., there is no AAV rep or cap DNA between the ITRs of the rAAV genome. In some embodiments, the AAV is recombinant linear AAV (rAAV), single-stranded AAV (ssAAV), or recombinant self-complementary AAV (scAAV).
[0080] Therefore, this disclosure provides packaging cells that produce infectious rAAV in several embodiments. In one embodiment, the packaging cells are stably transformed cancer cells such as HeLa cells, 293 cells, and PerC.6 cells (congeneral 293 strain). In another embodiment, the packaging cells are non-cancer cells that have been transformed, such as low-passage 293 cells (human fetal kidney cells transformed with adenovirus E1), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells), and FRhL-2 cells (rhesus monkey fetal lung cells).
[0081] In some embodiments, rAAV is purified by methods standard in the art, for example, by column chromatography or a cesium chloride gradient. Methods for purifying rAAV vectors from helper viruses are known in the art and are disclosed, for example, in Clark et al., Hum. Gene Ther., 10(6):1031-1039 (1999), Schenpp and Clark, Methods Mol. Med., 69 427-443 (2002), U.S. Patent No. 6,566,118 and WO98 / 09657.
[0082] In some embodiments, this disclosure provides compositions or a number of compositions comprising nucleic acids or vectors, such as viral vectors, as described herein. Thus, compositions comprising delivery vehicles (such as rAAV) as described herein are provided. In various embodiments, such compositions also comprise pharmaceutically acceptable carriers. In various embodiments, such compositions also comprise other components such as diluents, excipients, and / or adjuvants. Acceptable carriers, diluents, excipients, and adjuvants are nontoxic to the recipient, preferably inactive at the dose and concentration used, and include buffers such as phosphoric acid, citrate, or other organic acids; antioxidants such as ascorbic acid; proteins such as low molecular weight polypeptides, serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparaginine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as tween, pluronic, or polyethyl glycol (PEG).
[0083] In some embodiments, the nucleic acid is introduced into a vector for delivery. In some embodiments, the vector for delivery is an AAV or an rAAV. Thus, embodiments of the present disclosure include an rAAV genome comprising a nucleic acid comprising (i) a nucleotide sequence shown in any of SEQ ID NOs: 1 to 18, or a variant thereof having at least about 90% sequence identity with the sequence shown in any of SEQ ID NOs: 1 to 18, or (ii) a nucleotide sequence encoding a DUX4asRNA that binds to a DUX4 target sequence shown in any of SEQ ID NOs: 19 to 36.
[0084] In some other embodiments, the nucleic acid is introduced into the cell via non-vectorized delivery. Thus, in embodiments, the disclosure includes non-vectorized delivery of a nucleic acid encoding DUX4asRNA. In some embodiments, in this context, a synthetic carrier that forms a complex with the nucleic acid and protects them from extracellular and intracellular nucleases is an alternative to viral vectors. The disclosure includes such non-vectorized delivery. The disclosure also includes compositions comprising any of the constructs described herein, alone or in combination.
[0085] The sterile injectable solution is prepared by incorporating the rAAV in the required amount into a suitable solvent, optionally together with various other ingredients enumerated above, and subsequently filtering the solution under sterile conditions. In general, the dispersions are prepared by incorporating the sterile active ingredient into a sterile vehicle containing a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred method of preparation is by vacuum drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredients from those solutions which have been previously sterile filtered.
[0086] The titer of rAAV administered by the methods of the disclosure can vary, for example, depending on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type being targeted, and can be determined by standard methods in the art. The titer of rAAV can be in the range of about 1×10 6 particles per ml, about 1×10 7 particles per ml, about 1×10 8 particles per ml, about 1×10 9 particles per ml, about 1×10 10 particles per ml, about 1×10 11 particles per ml, about 1×10 12 particles per ml, about 1×10 13 to about 1×10 14 particles per ml, or more, and can be in the range of DNase-resistant particles (DRP). The dosage can also be expressed in units of viral genome (vg) (e.g., 1×10 7 vg, 1×10 8 vg, 1×10 9 vg, 1×10 10 vg, 1×1011 vg, 1×10 12 vg, 1×10 13 vg, and 1 × 10 14 (vg).
[0087] Accordingly, in some embodiments, the Disclosure provides a method for delivering to a cell or subject any one or more nucleic acids comprising (i) a polynucleotide encoding U7-asDUX4 antisense, which includes a nucleotide sequence shown in any one of SEQ ID NOs: 1 to 18, or a variant thereof having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with any one of the sequences shown in SEQ ID NOs: 1 to 18, and / or (ii) a polynucleotide encoding U7-asDUX4 antisense that targets a DUX4 sequence including a nucleotide sequence shown in any one of SEQ ID NOs: 19 to 36.
[0088] In some embodiments, the method involves administering to a cell or subject an AAV comprising (i) a polynucleotide encoding U7-asDUX4 antisense, comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1-18, or a variant thereof having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with any one of the sequences represented by SEQ ID NOs: 1-18, and / or (ii) a polynucleotide encoding U7-asDUX4 antisense that targets a DUX4 sequence comprising a nucleotide sequence represented by any one of SEQ ID NOs: 19-36.
[0089] In yet another embodiment, the Disclosure provides a method for reducing the expression of the DUX4 gene or functional DUX4 in a cell or subject, the method comprising contacting the cell or subject with any one or more nucleic acids comprising (i) a polynucleotide encoding U7-asDUX4 antisense, which includes a nucleotide sequence represented by any one of SEQ ID NOs: 1-18, or a variant thereof having at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with any one of the sequences represented by SEQ ID NOs: 1-18, and / or (ii) a polynucleotide encoding U7-asDUX4 antisense that targets a DUX4 sequence including a nucleotide sequence represented by any one of SEQ ID NOs: 19-36.
[0090] In some embodiments, the method comprises delivering nucleic acids in one or more AAV vectors. In some embodiments, the method comprises delivering nucleic acids to cells by non-vectorized delivery.
[0091] In some embodiments, DUX4 expression or functional DUX4 expression is reduced by at least or about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% in cells or subjects by the methods provided herein.
[0092] In some embodiments, the Disclosure provides AAV-transduced cells for the delivery of nucleic acids encoding the U7-asDUX4 antisense construct described herein. Methods for transducing target cells with rAAV in vivo or in vitro are included in the Disclosure. The methods include the step of administering an effective dose or multiple effective doses of a composition comprising rAAV of the Disclosure to a subject, including an animal (such as a human) that requires it. If the dose is administered before the onset of muscular dystrophy, the administration is prophylactic. If the dose is administered after the onset of muscular dystrophy, the administration is therapeutic. In embodiments of the Disclosure, the effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the muscular dystrophy being treated, delays or prevents the progression of the muscular dystrophy, reduces the severity of the disease, results in remission (partial or complete) of the muscular dystrophy, and / or prolongs survival. In some embodiments, the muscular dystrophy is FSHD.
[0093] Combination therapies are also contemplated in this disclosure. Combinations as used herein include concurrent or sequential therapies. Combinations of the methods disclosed herein with standard medical treatments (e.g., corticosteroids and / or immunosuppressants) or other inhibitory RNA constructs are specifically contemplated, as are combinations with other therapies, such as those disclosed in International Publication No. 2013 / 016352, which are incorporated herein by reference in their entirety.
[0094] The effective dose of the composition may be administered via a standard route in the art, including but not limited to intramuscular, parenteral, intravascular, intravenous, oral, buccal, nasal, lung, intracranial, intraventricular, intrathecal, intraosseous, intrafocal, intraocular, rectal, or vaginal. The route of administration and serotype of the AAV components of the rAAV of this disclosure (in particular, AAV ITR and capsid protein) may be selected and / or adapted by those skilled in the art, taking into account the disease condition being treated and target cells / tissues such as cells expressing DUX4. In some embodiments, the route of administration is intramuscular. In some embodiments, the route of administration is intravenous.
[0095] In some embodiments, the actual administration of rAAV according to this disclosure can be achieved by using any physical method for transporting the rAAV recombinant vector to a target tissue in an animal. Administration according to this disclosure includes, but is not limited to, injection into muscle, bloodstream, the central nervous system, and / or direct injection into the brain or other organs. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that can be administered co-administered with rAAV (however, compositions that degrade DNA should be avoided by conventional means using rAAV). The capsid protein of rAAV may be modified so that rAAV targets a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have already been developed and can be put into practice according to this disclosure. rAAV can be used with any pharmaceutically acceptable carrier to facilitate administration and handling.
[0096] For intramuscular injection, adjuvant solutions such as sesame oil or peanut oil, aqueous propylene glycol solutions, and sterile aqueous solutions can be used. Such aqueous solutions can be buffered as needed, and the liquid diluent can be isotonic first with physiological saline or glucose. Solutions of rAAV as free acid (DNA containing acidic phosphate groups) or pharmacokinetically acceptable salts can be prepared in water suitably mixed with a surfactant such as hydroxypropyl cellulose. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, as well as in oil. Under normal storage and use conditions, these preparations contain preservatives that prevent microbial growth. In this regard, all sterile aqueous media used can be readily obtained by standard techniques well known to those skilled in the art.
[0097] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid enough to be readily usable in a syringe. It must be stable under manufacturing and storage conditions and protected against microbial contamination such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. In some embodiments, adequate fluidity is maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial action can be provided by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it would be preferable to include an isotonic agent, such as sugar or sodium chloride. The prolonged absorption of injectable compositions can be achieved by using absorption-delaying agents, such as aluminum monostearate and gelatin.
[0098] In some embodiments, the formulation includes a stabilizer. The term “stabilizer” refers to a substance or excipient that protects the formulation from adverse conditions, such as those occurring during heating or freezing, and / or extends the stability or shelf life of the formulation in a stable state. Examples of stabilizers include, but are not limited to, sugars such as sucrose, lactose, and mannose; sugar alcohols such as mannitol; amino acids such as glycine or glutamic acid; and proteins such as human serum albumin or gelatin.
[0099] In some embodiments, the formulation includes an antimicrobial preservative. The term “antimicrobial preservative” refers to any substance added to the composition that inhibits the growth of microorganisms that may be introduced during repeated punctures of the vial or container used. Examples of antimicrobial preservatives include, but are not limited to, thimerosal, 2-phenoxyethanol, benzethonium chloride, and phenol.
[0100] The term "transduction" is used to refer to the administration / delivery of one or more nucleic acids described herein to recipient cells, either in vivo or in vitro, via the replication-deficient rAAV of this disclosure, resulting in the expression of DUX4miRNA by the recipient cells.
[0101] In one embodiment, transduction with rAAV is performed in vitro. In one embodiment, desired target cells are isolated from a subject, transduced with rAAV, and reintroduced into the subject. Alternatively, syngeneic or heterologous cells can be used if those cells do not produce an inappropriate immune response in the subject.
[0102] Suitable methods for transduction into a target and reintroduction of transduced cells are known in the art. In one embodiment, cells are transduced in vitro by combining them with rAAV in, for example, a suitable culture medium, and these cells having the DNA of the target are screened using conventional techniques such as Southern blotting and / or PCR, or using a selectable marker. The transduced cells are then formulated into a pharmaceutical composition, and the composition can be introduced into a target by various techniques, such as intramuscular, intravenous, subcutaneous, and intraperitoneal injection, or by injection into smooth muscle and cardiac muscle using, for example, a catheter.
[0103] This disclosure provides a method for administering an effective dose (or essentially concurrently administered doses or intervally doses) of rAAV, comprising DNA encoding a microRNA designed to downregulate or inhibit DUX4 expression, to cells or subjects requiring it. In some embodiments, the effective dose is therefore a therapeutically effective dose.
[0104] In some embodiments, the dose or effective dose of rAAV administered is approximately 1.0 × 10⁻⁶ 10 vg / kg ~ approx. 1.0×10 16 It is vg / kg. In some embodiments, 1.0 × 10 10 vg / kg is also expressed as 1.0E10vg / kg, which is simply an alternative way of showing scientific notation. Similarly, 10 11 For example, it is equivalent to E11. In some embodiments, the dose of rAAV administered is approximately 1.0 × 10⁻⁶. 11 vg / kg ~ approx. 1.0×10 15 The value is vg / kg. In some embodiments, the dose of rAAV is approximately 1.0 × 10⁻⁶. 10 vg / kg, approx. 2.0×10 10 vg / kg, approx. 3.0×10 10 vg / kg, approximately 4.0×10 10 vg / kg, approximately 5.0×10 10 vg / kg, approximately 6.0×10 10 vg / kg, approximately 7.0×10 10 vg / kg, approximately 8.0×10 10 vg / kg, approximately 9.0×10 10 Approximately 1.0×10 11 vg / kg, approx. 2.0×10 11 vg / kg, approx. 3.0×10 11 vg / kg, approximately 4.0×10 11 vg / kg, approximately 5.0×10 11 vg / kg, approximately 6.0×10 11 vg / kg, approximately 7.0×10 11 vg / kg, approximately 8.0×10 11 vg / kg, approximately 9.0×10 11 vg / kg, approximately 1.0×10 12vg / kg, approx. 2.0×10 12 vg / kg, approx. 3.0×10 12 vg / kg, approximately 4.0×10 12 vg / kg, approximately 5.0×10 12 vg / kg, approximately 6.0×10 12 vg / kg, approximately 7.0×10 12 vg / kg, approximately 8.0×10 12 vg / kg, approximately 9.0×10 12 vg / kg, approximately 1.0×10 13 vg / kg, approx. 2.0×10 13 vg / kg, approx. 3.0×10 13 vg / kg, approximately 4.0×10 13 vg / kg, approximately 5.0×10 13 vg / kg, approximately 6.0×10 13 vg / kg, approximately 7.0×10 13 vg / kg, approximately 8.0×10 13 vg / kg, approximately 9.0×10 13 vg / kg, approximately 1.0×10 14 vg / kg, approx. 2.0×10 14 vg / kg, approx. 3.0×10 14 vg / kg, approximately 4.0×10 14 vg / kg, approximately 5.0×10 14 vg / kg, approximately 6.0×10 14 vg / kg, approximately 7.0×10 14 vg / kg, approximately 8.0×10 14 vg / kg, approximately 9.0×10 14 vg / kg, approximately 1.0×10 15 vg / kg, approx. 2.0×10 15 vg / kg, approx. 3.0×10 15 vg / kg, approximately 4.0×10 15 vg / kg, approximately 5.0×10 15 vg / kg, approximately 6.0×10 15 vg / kg, approximately 7.0×10 15 vg / kg, approximately 8.0×10 15 vg / kg, approximately 9.0×10 15 vg / kg, or approximately 1.0 × 10⁻⁶ 16 It is vg / kg.
[0105] In some embodiments, the dose is approximately 1.0 × 10 11 vg / kg ~ approx. 1.0×10 15 The value is vg / kg. In some embodiments, the dose is approximately 1.0 × 10⁻⁶. 13 vg / kg ~ approx. 5.0×10 13 The value is vg / kg. In some embodiments, the dose is approximately 2.0 × 10⁻⁶. 13 vg / kg ~ approx. 4.0×10 13 The value is vg / kg. In some embodiments, the dose is approximately 3.0 × 10⁻⁶. 13 It is vg / kg.
[0106] In some embodiments, an initial dose is followed by a second, higher dose. In some embodiments, an initial dose is followed by a second, same dose. In some embodiments, an initial dose is followed by one or more smaller doses. In some embodiments, an initial dose is followed by multiple doses that are the same or higher doses.
[0107] Methods for transducing target cells in vivo or in vitro with a delivery vehicle (e.g., rAAV) are envisioned. Transduction of cells with rAAV as described herein results in sustained expression of a DUX4 antisense sequence. Thus, in some embodiments, the disclosure provides rAAVs expressing antisense sequences that bind to key exon-defining elements in premRNA and methods for administering / delivering rAAVs, thereby inhibiting the recognition of specific exons by spliceosomes and resulting in the exclusion of target exons from mature RNA in the subject. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human. These methods involve transducing cells and tissues (including, but not limited to, tissues such as muscle) with one or more rAAVs as described herein. Transduction may be performed using gene cassettes containing cell-specific regulatory elements. The term "transduction" refers, for example, to the administration / delivery of u7snRNA containing an antisense sequence, e.g., U7-asDUX4, to target cells either in vivo or in vitro via replication-deficient rAAV as described herein, resulting in reduced or inhibited expression of DUX4 by the target cells.
[0108] An in vivo method includes the step of administering an effective dose or multiple effective doses of a composition comprising a delivery vehicle (such as rAAV) to a subject (including a human subject) that requires it. Thus, a method is provided for administering an effective dose (or doses administered essentially simultaneously or at intervals) of the rAAV described herein to a patient that requires it. If the dose or multiple doses are administered before the onset of the disorder / disease, the administration is prophylactic. If the dose or multiple doses are administered after the onset of the disorder / disease, the administration is therapeutic. An effective dose is one that alleviates (eliminates or reduces) at least one symptom associated with the disorder / disease condition being treated, delays or prevents progression to the disorder / disease condition, delays or prevents progression to the disorder / disease condition, reduces the severity of the disease, results in remission (partial or complete) of the disorder / disease condition, and / or prolongs survival.
[0109] In some embodiments, the compositions and methods of this disclosure are used in treating, improving, or preventing diseases such as muscular dystrophy (MD). In various embodiments, such MD is FSHD. FSHD is the most commonly inherited muscular dystrophy, and is estimated to affect as many as 870,000 people. The classic description of FSHD symptoms includes progressive weakness in the face, shoulder girdle, and arms, but the disease can manifest more broadly, including the muscles of the torso and lower extremities. Variability is also commonly observed within individuals, and asymmetrical weakness is common. The age of onset can range from infancy to adulthood and is usually related to the severity of the disease, with earlier onset often associated with more severe weakness. Most patients with FSHD have a normal lifespan, but respiratory failure can occur, the disease can be debilitating, and about 25% of affected individuals may become wheelchair dependent by their 50s, even earlier in more severe forms of the disease, while others maintain walking for life.
[0110] FSHD is caused by the abnormal expression of the double homeobox 4 gene (DUX4), which produces transcription factors toxic to skeletal muscle. DUX4 normally functions during the two-cell stage of human development, but is subsequently suppressed in virtually all other tissues, except perhaps the testes. In the skeletal muscle of individuals with FSHD, certain genetic and epigenetic factors simultaneously enable DUX4 derepression, which then initiates a cascade of abnormal gene expression, including those involved in differentiation abnormalities, oxidative stress, inflammatory infiltration, cell death, and muscle atrophy.
[0111] In families known to have pathological FSHD, the methods of the present disclosure are, in various embodiments, methods for preventing the disease, and they are performed before the onset of the disease. In other various embodiments, the methods of the present disclosure are performed after diagnosis and are therefore methods for treating or improving the disease.
[0112] In some embodiments, the compositions and methods of this disclosure are used in treating, improving, or preventing diseases such as cancer. DUX4 has been shown to be activated in several cancer types, and it functions to mask tumor cells from the immune system (Chew et al., Dev. Cell 2019 Sep 9;50(5):658-71). For example, DUX4 protein fusion is known to cause cancers such as rhabdomyosarcoma and Ewing's sarcoma. CIC-DUX4 gene fusion induces sarcoma and drives sarcoma metastasis (Yoshimoto et al., Cancer Res. 2017 Jun 1;77(11):2927-2937, Okimoto et al., J Clin Invest. 2019;129(8):3401-3406). Therefore, the nucleic acids, rAAVs, and compositions described herein are used in inhibiting DUX4 expression in the treatment, improvement, or prevention of cancer.
[0113] Molecular, biochemical, histological, and functional outcome measures demonstrate the therapeutic efficacy of the products and methods disclosed herein in reducing the expression of the DUX4 gene and protein and treating muscular dystrophy such as FSHD. Outcome measures are, for example, those found in Dyck and Thomas, Peripheral Neuropathy, Elsevier Saunders, Philadelphia, PA, 4. th This is described in Chapters 32, 35, and 43 of Edition, Volume 1 (2005), and in Burgess et al., Methods Mol. Biol., 602:347-393 (2010). Outcome measures include, but are not limited to, a decrease or removal of DUX4 mRNA or protein in affected tissue. Absence of DUX4 expression in cells and / or downregulation of DUX4 expression are detected by measuring the level of DUX4 protein in muscle biopsies before and after rAAV administration by methods known in the art, including, but not limited to, RT-PCR, qRT-PCR, RNAscope, Western blotting, immunofluorescence, or immunohistochemistry, in order to determine improvement.
[0114] In some embodiments, the level of DUX4 gene expression or protein expression in the target cells is reduced after administration of an antisense snRNA construct or a vector containing an antisense snRNA construct, e.g., rAAV, compared to the level of DUX4 gene expression or protein expression before administration of an antisense snRNA construct or vector, e.g., rAAV. In some embodiments, DUX4 expression is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, at least about 100%, or by more than about 100%. In various embodiments, improved muscle strength, improved muscle function, and / or improved mobility and stamina show improvements of at least about 2%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, at least about 100%, or at least about 100% or more.
[0115] Other outcome measures include measuring serum creatinine kinase (CK) levels in subjects before and after treatment. Elevated CK levels are characteristic of muscle damage. In patients with muscular dystrophy, CK levels are significantly elevated beyond the normal range (10 to 100 times the normal level since birth). When elevated CK levels are detected in a blood sample, it usually means that the muscle is being broken down by some abnormal process, such as muscular dystrophy or inflammation. Therefore, a positive therapeutic outcome in treatment by the method of this disclosure is a decrease in serum creatinine kinase levels after administration of rAAV compared to serum creatinine kinase levels before administration of rAAV.
[0116] Other outcome measures include those used to determine whether there is an improvement in muscle strength, muscle function, mobility, stamina, or a combination of two or more of these in subjects after treatment. Such outcome measures are important in determining the progression of muscular dystrophy in subjects and are measured by a variety of tests known in the art. Some of these tests include, but are not limited to, the 6-minute walk test, stand-to-stand time test, 4-step up-and-down test, Northstar gait assessment (NSAA) test, 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD) test, timed up-and-go test, gross motor subtest scale (Bayley-III) score, maximal voluntary isometric contraction test (MVICT), or a combination of two or more of these.
[0117] Combination therapies are also included in this disclosure. Combinations used herein include both concurrent and sequential therapies. Combinations of the methods described herein with standard medical treatments and supportive therapies are specifically intended, as are combinations with therapies such as glucocorticoids. All types of glucocorticoids are included for use in the combination therapies disclosed herein. Such glucocorticoids include, but are not limited to, prednisone, prednisolone, dexamethasone, deflazacort, beclomethasone, betamethasone, budesonide, cortisone, hydrocortisone, methylprednisolone, and triamcinolone.
[0118] Other combination therapies included in this disclosure are combinations of U7-snRNA with other U7-snRNAs, or miRNA-based gene therapies, small molecule inhibitors of DUX4 expression, oligonucleotides that inhibit DUX4 via RNAi, or combinations with RNAse H or exon skipping mechanisms, or U7-snRNA plus theoretical CRISPR-based gene therapy approaches.
[0119] The administration of an effective dose of the nucleic acids, viral vectors, or compositions of this disclosure may be by routes standard in the art, including but not limited to intramuscular, parenteral, intravascular, intravenous, oral, buccal, nasal, lung, intracranial, ventricular, intrathecal, intraosseous, intraocular, rectal, or vaginal. In some embodiments, the effective dose is delivered by a systemic route of administration, i.e., systemic administration. Systemic administration is a route of administration to the circulatory system such that the entire body is affected. Such systemic administration is carried out in various embodiments by enteral administration (absorption of the drug through the gastrointestinal tract) or parenteral administration (generally via injection, infusion, or implantation). In various embodiments, the effective dose is delivered by a combination of routes. For example, in various embodiments, the effective dose is delivered intravenously and / or intramuscularly, or intravenously and ventricularly, etc. In some embodiments, the effective dose is delivered sequentially or consecutively. In some embodiments, the effective dose is delivered simultaneously. The routes of administration and serotypes of the AAV components of the rAAVs of this disclosure (in particular, AAV ITR and capsid proteins) are selected and / or adapted by those skilled in the art in various embodiments, taking into consideration the context or state of the disease or disorder being treated, the context, state, or age of the subject, and the target cells / tissues that should express the nucleic acids or proteins.
[0120] In particular, the actual administration of a delivery vehicle (such as rAAV) can be achieved by using any physical method to transport the delivery vehicle (such as rAAV) to target cells in an animal. Administration includes, but is not limited to, injection into muscle, bloodstream, and / or direct nervous system or liver. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that can be administered co-administered with rAAV (however, compositions that degrade DNA should be avoided by the usual means of using rAAV). The capsid protein of rAAV may be modified so that rAAV targets specific target tissues of interest, such as nerve cells. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have already been developed and can be used in the implementation of this disclosure. The delivery vehicle (such as rAAV) may be used with any pharmaceutically acceptable carrier to facilitate administration and handling.
[0121] Dispersions of delivery vehicles (such as rAAV) can also be prepared in glycerol, sorbitol, liquid polyethylene glycol, and mixtures thereof, as well as in oil. Under normal storage and use conditions, these preparations contain preservatives that prevent microbial growth. In this regard, all sterile aqueous media used can be readily obtained in standard techniques known to those skilled in the art.
[0122] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid enough to allow for easy syringe use. It must be stable under manufacturing and storage conditions and protected against microbial contamination such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, sorbitol, etc.), suitable mixtures thereof, and vegetable oils. Adequate fluidity can be maintained, for example, by the use of coating agents such as lecithin, by maintaining the required particle size in the case of dispersants, and by the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it would be preferable to include isotonic agents, such as sugars or sodium chloride. The prolonged absorption of injectable compositions can be achieved by using absorption-delaying agents, such as aluminum monostearate and gelatin.
[0123] Sterile injectable solutions are prepared by incorporating rAAV in the required amount into a suitable solvent, along with various other components listed above as needed, followed by sterilization by filtration. Generally, dispersants are prepared by incorporating the sterilized active ingredient into a sterile vehicle containing a basic dispersion medium and other required components from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired components from those solutions that have been previously sterilized and filtered.
[0124] "To treat" includes improving or inhibiting one or more symptoms of muscular dystrophy, including but not limited to muscle wasting, muscle weakness, muscle tension, skeletal muscle problems, retinal abnormalities, hip weakness, facial weakness, abdominal muscle weakness, joint and spinal abnormalities, lower limb weakness, shoulder weakness, hearing loss, muscle inflammation, and asymmetrical weakness.
[0125] The administration of an effective dose of the nucleic acids, viral vectors, or compositions of this disclosure may be by routes standard in the art, including but not limited to intramuscular, parenteral, intravascular, intravenous, oral, buccal, nasal, lung, intracranial, ventricular, intrathecal, intraosseous, intraocular, rectal, or vaginal. In some embodiments, the effective dose is delivered by a systemic route of administration, i.e., systemic administration. Systemic administration is a route of administration to the circulatory system such that the entire body is affected. Such systemic administration is carried out in various embodiments by enteral administration (absorption of the drug through the gastrointestinal tract) or parenteral administration (generally via injection, infusion, or implantation). In various embodiments, the effective dose is delivered by a combination of routes. For example, in various embodiments, the effective dose is delivered intravenously and / or intramuscularly, or intravenously and ventricularly, etc. In some embodiments, the effective dose is delivered sequentially or consecutively. In some embodiments, the effective dose is delivered simultaneously. The routes of administration and serotypes of the AAV components of the rAAVs of this disclosure (in particular, AAV ITR and capsid proteins) are selected and / or adapted by those skilled in the art in various embodiments, taking into account the context or state of the disease or disorder being treated, the context, state, or age of the subject, and the target cells / tissues that should express the nucleic acids or proteins.
[0126] In particular, the actual administration of a delivery vehicle (such as rAAV) can be achieved by using any physical method to transport the delivery vehicle (such as rAAV) to target cells in an animal. Administration includes, but is not limited to, injection into muscle, bloodstream, and / or direct nervous system or liver. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that can be administered co-administered with rAAV (however, compositions that degrade DNA should be avoided by the usual means of using rAAV). The capsid protein of rAAV may be modified so that rAAV targets specific target tissues of interest, such as nerve cells. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have already been developed and can be put into practice in this disclosure. The delivery vehicle (such as rAAV) may be used with any pharmaceutically acceptable carrier to facilitate administration and handling.
[0127] Dispersions of delivery vehicles (such as rAAV) can also be prepared in glycerol, sorbitol, liquid polyethylene glycol, and mixtures thereof, as well as in oil. Under normal storage and use conditions, these preparations contain preservatives that prevent microbial growth. In this regard, all sterile aqueous media used can be readily obtained in standard techniques known to those skilled in the art.
[0128] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid enough to allow for easy syringe use. It must be stable under manufacturing and storage conditions and protected against microbial contamination such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, sorbitol, etc.), suitable mixtures thereof, and vegetable oils. Adequate fluidity can be maintained, for example, by the use of coating agents such as lecithin, by maintaining the required particle size in the case of dispersants, and by the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it would be preferable to include isotonic agents, such as sugars or sodium chloride. The prolonged absorption of injectable compositions can be achieved by using absorption-delaying agents, such as aluminum monostearate and gelatin.
[0129] Sterile injectable solutions are prepared by incorporating rAAV in the required amount into a suitable solvent, along with various other components listed above as needed, followed by sterilization by filtration. Generally, dispersants are prepared by incorporating the sterilized active ingredient into a sterile vehicle containing a basic dispersion medium and other required components from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired components from those solutions that have been previously sterilized and filtered.
[0130] This disclosure also provides kits comprising or manufactured according to the processes of this disclosure, comprising the nucleic acids, vectors, or compositions of this disclosure. In the context of this disclosure, the term “kit” means two or more components, one of which corresponds to the nucleic acids, vectors, or compositions of this disclosure, and the other to a container, recipient, instructions, or other. Thus, a kit is, in various embodiments, a set of products sufficient to achieve a particular objective and can be sold as a single unit.
[0131] The kit may include one or more recipients (such as vials, ampoules, containers, syringes, bottles, bags, etc.) of any suitable shape, size, and material containing the nucleic acids, vectors, or compositions of this disclosure in an appropriate dose for administration (see above). The kit may further include instructions or instructions for use (e.g., in the form of a leaflet or instruction manual), means such as syringes, pumps, injectors for administering the nucleic acids, vectors, or compositions, means for reconstituting the nucleic acids, vectors, or compositions, and / or means for diluting the nucleic acids, vectors, or compositions.
[0132] In some embodiments, the kit includes a label and / or instructions describing the use of the reagents provided in the kit. The kit also optionally includes a catheter, syringe, or other delivery device for delivering one or more of the compositions used in the methods described herein.
[0133] The present invention also provides kits for single-dose or multi-dose administration units. In some embodiments, the disclosure provides kits comprising single-chamber and multi-chamber prefilled syringes.
[0134] The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features is not found together in the same sentence, paragraph, or section of this document. The disclosure also includes all embodiments of the disclosure, for example, that are somewhat narrower in scope than the variations specifically mentioned above. With respect to aspects of the disclosure described as a genus, all individual species are considered distinct aspects of the disclosure. With respect to aspects of the disclosure described or claimed as "a" or "an," it should be understood that these terms mean "one or more" unless the context explicitly requires a more limited meaning.
[0135] Unless otherwise specified, the term “at least” preceding a set of elements should be understood to refer to all elements in that set. Those skilled in the art will be able to recognize, or verify by use without going beyond routine experimentation, many equivalents to the specific embodiments of this disclosure described herein. Such equivalents are intended to be encompassed by this disclosure.
[0136] As used herein, the terms "and / or" include, at any time, "and," "or," and "all or any other combination of the elements connected by such terms." As used herein, the terms “about” or “approximately” mean within 20%, preferably within 10%, and more preferably within 5% of a given value or range. However, it also includes specific numbers; for example, “about 10” includes 10.
[0137] Throughout this specification and the subsequent claims, unless otherwise required by context, the word “comprise,” and variations such as “comprises” and “comprising,” should be understood to mean including any integer or step or group of integers or steps described, but not to mean excluding any other integer or step or group of integers or steps. Where used herein, the term “comprising” may be replaced by the terms “containing” or “including,” or, where sometimes used herein, by the term “having.”
[0138] As used herein, “consisting of” excludes any element, step, or component not specified in the elements of the claims. As used herein, “essentially consisting of” does not exclude any material or step that does not substantially affect the basic and novel features of the claims.
[0139] In the examples herein, any of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced by any of the other two terms.
[0140] This disclosure is not limited to, and is therefore subject to change, the specific methodologies, protocols, materials, reagents, and substances described herein. Terms used herein are intended solely to describe specific embodiments and are not intended to limit the scope of the subject matter defined solely by the claims.
[0141] All publications and patents cited throughout this Specified (including all patents, patent applications, scientific publications, manufacturer specifications, instructions, etc.) are incorporated herein by reference in their entirety, whether above or below. To the extent that any material incorporated by reference is inconsistent with or contradicts this Specified, this Specified shall prevail over any such material.
[0142] A better understanding of this disclosure and its merits will be obtained from the following examples, which are provided for illustrative purposes only. The examples are not intended to limit the scope of this disclosure. The examples and embodiments described herein are for illustrative purposes only, and various modifications or changes in their respects will be suggested to those skilled in the art, but should be understood to be included within the spirit and scope of this application and the scope of the appended claims. [Examples]
[0143] Additional aspects and details of this disclosure will be apparent from the following examples, which are intended to be illustrative rather than limiting. Example 1 Materials and methods Design of DUX4-targeted U7-snRNA Using the Human Splicing Finder version 3.1 program at Marseille University (http-colon-slash-slash-www.umd.be-slash-HSF-slash), potential splice acceptor (SA), splice donor (SD), and splice enhancer sites were predicted at the end of DUX4 exon 1 (coding sequence) and within untranslated exons 1 and 2. To design U7-snRNA for DUX4 (referred to as U7-asDUX4), 18 high-scoring target sites with the fewest CpGs and one non-target region were selected (Table 1). Predicted out-of-target fits were determined by BLAST using each sequence against the Human Genome Database (https colon-slash-slash-blast.ncbi.nlm.nih.gov). Expression cassettes of all U7-asDUX4 containing the mouse U7 promoter were synthesized and cloned into pUCIDT plasmids (Integrated DNA Technologies, Coralville, Iowa). The sequence was also designed to bind to the DUX4 start codon and poly(A) signal via reverse complementary base pairing (Table 1). The untargeted control snRNA antisense sequence is 5'-GTCATGTCGCGTGCCCCGGTGGTCGACACGTCGG-3' (SEQ ID NO: 43).
[0144] cell culture Human fetal kidney (HEK293) cells were cultured at 37°C in 5% CO2 in DMEM supplemented with 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin / streptomycin. Immortalized and unaffected human myoblasts derived from human FSHD patients, as well as 15Abic and 15Vbic (40,60) for comparison with the unaffected group, were expanded in DMEM medium supplemented with 16% Medium 199, 20% fetal bovine serum, 1% penicillin / streptomycin, 30 ng / ml zinc sulfate, 1.4 mg / ml vitamin B12, 55 ng / ml dexamethasone, 2.5 ng / ml human growth factor, 10 ng / ml fibroblast growth factor, and 20 mM HEPES. The cells were maintained as myoblasts and differentiated for DUX4 and DUX4 activity biomarker screening by qRT-PCR and RNAscope. To differentiate myoblasts into myotubes, transfected myoblasts were transferred to a differentiation medium consisting of 4:1 DMEM:Medium199 supplemented with 15% KnockOut Serum (ThermoFisher Scientific), 2 mM L-glutamine, and 1% antibiotics / antimycobiotics for up to 7 days prior to collection.
[0145] Survival rate assay HEK293 cells (250,000 cells / well) were co-transfected in a 1:6 ratio using a protocol (Lipofectamine-2000, Invitrogen) with an expression plasmid containing full-length DUX4 premRNA (DUX4-fl) transcribed from the cytomegalovirus (CMV) promoter (CMV.DUX4-fl), along with a plasmid expressing either U7-asDUX4 snRNA or untargeted U7-snRNA. Cells were trypsinized 48 hours after transfection and collected in 1 ml of growth medium. Automated cell counting was performed using a Countess® cell counting chamber slide (Thermo Fisher). Results were confirmed by conventional cell counting using a hemocytometer and trypan blue staining. Three independent experiments were performed, and data are reported as mean ± SEM total cell count per group.
[0146] Cell death assay HEK293 cells (42,000 cells / well) were seeded in 96-well plates 16 hours before transfection. The following morning, cells were co-transfected with CMV.DUX4-fl and U7-asDUX4 snRNA or untargeted U7-snRNA expression plasmids in a 1:6 molar ratio (Lipofectamine-2000, Invitrogen). Cell death was measured 48 hours after transfection using the Apo-ONE Homogeneous Caspase-3 / 7 Assay (Promega, Madison, WI) and a fluorescence plate reader (Spectra Max M2, Molecular Devices, Sunnyvale, CA). Three individual assays were performed in triple replication (n=3), and data were averaged for each experiment. The mean caspase activity ± SEM was reported compared to a control assay transfected with CMV.DUX4-fl alone.
[0147] Western blot assay In this experiment, DUX4 expression plasmids were used with and without an epitope tag (CMV.Myc-DUX4-fl or CMV-DUX4-fl containing a myc epitope tag fused to the N-terminus of DUX4). HEK293 cells were co-transfected with a 1:6 ratio DUX4:U7asDUX4 expression plasmid. Twenty hours after transfection, cells were dissolved in RIPA buffer supplemented with a cocktail containing protease inhibitors (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X100). Protein concentrations were determined using the Lowry Protein Assay Kit (Bio-Rad Laboratories). 25 μg of each total protein sample was developed on a 12% SDS-polyacrylamide gel. Proteins were transferred to a PVDF membrane via a semi-dry transfer method, then blocked with 5% skim milk, and incubated overnight at 4°C with primary monoclonal mouse anti-DUX4 (1:500, P4H2, Novus Biologicals), mouse anti-Myc (R95125, Invitrogen), or rabbit polyclonal anti-α-tubulin antibody (1:1,000, ab15246, Abcam, Cambridge, MA). The following day, after multiple washes, the blots were explored at room temperature for 1 hour using horseradish peroxidase (HRP) conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1:100,000, Jackson ImmunoResearch, West Grove, PA). After short incubation in Immobilon Chemiluminescent HRP substrate (Millipore, Billerica, MA), relative protein bands were developed on X-ray film. Protein quantification was evaluated using ImageJ software (National Institutes of Health, Bethesda, Maryland, USA, imagej.nih.gov / ij / ).
[0148] Immunofluorescence staining The intracellular localization of the V5 epitope-tagged DUX4 protein in treated and untreated cells was visualized using V5 immunofluorescence staining (Wallace et al. (2011) Ann Neurol69,540-552. This plasmid carried a full-length DUX4 sequence consisting of a coding sequence and a 3'UTR sequence, but was engineered to express the DUX4 protein with a carboxy-terminal V5 epitope fusion within the frame. Twenty hours after transfection, cells were fixed with 4% paraformaldehyde (PFA) for 20 minutes, and nonspecific antigens were blocked with 5% BSA in PBS supplemented with 0.2% TritonX-100. Cells were incubated overnight at 4°C in rabbit polyclonal anti-V5 primary antibody (1:2,500, Abcam, ab9116). The following day, cells were washed with PBS, incubated with goat anti-rabbit Alexa-594 secondary antibody (1:2,500, Invitrogen), and mounted in DAPI-containing Vectashield mounting medium (Vector Laboratories, Burlingame, CA).
[0149] RNAscope assay and quantification This study detected DUX4 overexpression in HEK293 cells. DUX4 mRNA levels were measured after co-transfection of HEK293 cells with CMV.DUX4-fl and U7.asDUX4 expression plasmids (1:6 ratio) using an RNAscope in situ hybridization assay. Specifically, HEK293 cells were triple-sampled onto glass coverslips in 24-well plates at a density of 120,000 cells per well 16 hours prior to transfection. The following morning, when the cells reached 70% density, they were co-transfected with 250 ng of CMV.DUX4-fl expression plasmid (Lipofectamine-2000, Thermo Fisher Scientific) according to the manufacturer's instructions. 16 hours after transfection, cells were fixed with 4% PFA and RNAscope staining was performed according to the manufacturer's instructions (details below).
[0150] This study aimed to detect endogenous DUX4 in human FSHD myotubes. To determine the specificity of U7-asDUX4 snRNA to targeted endogenous DUX4 mRNA, 15Abic FSHD myoblasts (15A, 500,000 cells / reaction) were transfected with a U7-asDUX4 expression plasmid via electroporation (Lonza, VVPD-1001) and then differentiated into myotubes for up to 7 days. RNAscope staining was performed as previously reported (Amini Chermahini, et al. (2019) RNA25, 1211-1217). Cells were fixed in 4% PFA and dehydrated / rehydrated with an ethanol gradient. Endogenous peroxidase activity was blocked by hydrogen peroxide treatment. Protease III was added to increase the permeability of cells fixed for RNAscope probes. Cells were treated with a DUX4-specific RNAscope probe (ACDBio, catalog No. 498541) or a probe that detects the positive control housekeeping peptidyl prolyl isomerase B (PPIB) and the negative control bacterial gene dihydrodipicolinic acid reductase (dapB). After probe incubation, cells were treated with RNAscope2.5HD Assay Brown using the manufacturer's protocol (ACDBio) in several signal amplification steps. Cells were counterstained with 50% Gill hematoxylin I (catalog No. HXGHE1LT, American Master Tech Scientific) at room temperature for 2 minutes, followed by several washes. After mounting, images were captured using an Olympus DP71 microscope. The DUX4 RNAscope signal was quantified using ImageJ-Fiji software as previously reported (30).
[0151] Quantitative Real-Time PCR Analysis of DUX4 Biomarkers 15A FSHD myoblasts were transfected as described in the RNAscope section herein and differentiated into myotubes. Total RNA content was extracted using TRIzol reagent (ThermoFisher) according to the manufacturer's protocol, and the yield was measured by Nanodrop. The isolated RNA was then DNase-treated (DNA-Free, Ambion, TX), and cDNA was constructed using a high-volume cDNA reverse transcription kit (Applied Biosystems) with random hexamer primers. The subsequent cDNA samples were then used as templates for Taqman assays using pre-designed TRIM43, MBD3L2, PRAMEF12, ZSCAN4 (biomarker for DUX4 activity), and human RPL13A control primer / probe sets (Applied Biosystems). All data were normalized to untargeted U7-snRNA transfected cells. Data for each biomarker were obtained from two independent experiments performed in triple assay.
[0152] statistical analysis All statistical analyses (caspase 3 / 7 assay, cell viability assay, RNAscope quantification, Western blot, qRT-PCR) were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA) with the statistical tests indicated.
[0153] Example 2 DUX4-targeted U7-snRNA reduces apoptosis and increases the survival rate of co-transfected HEK293.
[0154] Recombinant U7-snRNA was previously developed to induce skipping of mutated exons as a potential treatment for Duchenne muscular dystrophy (Goyenvalle et al. (2012) Mol Ther 20, 1212-1221) and β-thalassemia (Nualkaew et al. (2019) Sci Rep 9, 7672). In these studies, U7-snRNA was used to restore the expression of frameshifted genes by skipping entire exons. In contrast, the objective of this study was to develop novel gene silencing strategies using U7-snRNA by interfering with the maturation of DUX4 premRNA or inhibiting translation initiation (Biferi et al. (2017) Mol Ther 25, 2038-2052, Wein et al. (2014) Nat Med 20, 992-1000).
[0155] To accomplish this, we developed recombinant U7-snRNAs targeting splice donor (SD), splice acceptor (SA), and splice enhancer (SE) sequences, or the polyadenylation signal (PAS) in DUX4 exon 3 (Figure 1A-B). In addition, we constructed two constructs (9 and 10) positioned above the full-length DUX4 start codon that could potentially interfere with translation. The structures of these DUX4-targeted U7-snRNAs (referred to as U7-asDUX4) are shown in Figure 1A, and a key feature of their specificity is the antisense sequence modified to base-pair with various regions of the DUX4 premRNA. To select effective sequences for interfering with correct splicing, we used the Human Splicing Finder tool (Figure 5A-C) to predict potential SD, SA, and SE sites in all three DUX4 exons, as well as within introns 1 and 2. Subsequently, U7-asDUX4 was designed to target the highest-scoring site (Figure 1B). These U7-asDUX4s, targeting the polyA signal or start codon, ensured that the antisense sequence provided complete coverage of the congeneral sites on the DUX4 mRNA. All U7-asDUX4 sequences and their key features are summarized herein in Tables 1 and 2.
[0156] HEK293 cells do not normally express detectable DUX4, but are susceptible to DUX4-induced cell death after transfection with the CMV.DUX4 expression plasmid. Therefore, the efficacy of the U7-asDUX4 expression plasmid was first evaluated by measuring apoptotic cell death using caspase-3 / 7 and by cell viability assays as an outcome measure in co-transfected HEK293 cells. Eighteen U7-asDUX4 sequences were designed, and constructs were constructed and tested. Of these 18 constructs, thirteen significantly reduced cell death (50%) and increased viability (50%) in co-transfected HEK293 cells (Figure 1C-D). The most effective U7-asDUX4 constructs were constructs 4, 7, and 8, which targeted the exon 1-intron 1 junction or poly(A) signaling pathway (PAS). These constructs reduced caspase-3 / 7 activity by 75±7%, 60±9%, and 50±8%, respectively, and significantly increased viability by 78.5±8.4%, 94.8±4.9%, and 84.8±3.8%, respectively, compared to DUX4 alone (19.1±1.6%) or DUX4 using non-targeted U7-snRNA (23.3±0.5%), compared to other U7-asDUX4 constructs (Figure 1C-D). Due to their superior protective properties, U7-asDUX4 constructs 4, 7, and 8 appeared to be candidate read sequences.
[0157] Example 3 U7-asDUX4 significantly reduces DUX4 expression in transfected HEK293 cells.
[0158] The reduced DUX4-asDUX4 cell death outcomes in samples treated with the U7-asDUX4 plasmid suggested that these sequences were engineered to inhibit full-length DUX4 gene expression. To investigate the specificity of lead U7-asDUX4 sequences that appear to target and reduce DUX4 mRNA overexpressed in HEK293 cells, RNAscope in situ hybridization assays were initially used to detect DUX4 mRNA in co-transfected cells. Fixed cells were incubated with a DUX4-targeting probe, control transcript, or negative control reagent, and then treated with diaminobenzidine (DAB) reagent, which stains hybridized target mRNA brown. As previously reported (Amini Chermahini et al. (2019) RNA25, 1211-1217), cells transfected with DUX4 expression plasmids alone showed abundant, spider-like brown signaling, as well as relatively low cell density consistent with death, when incubated with the DUX4 probe (Figure 2A). In contrast, DUX4 probe signaling was significantly reduced in cells co-transfected with DUX4 and our three lead U7-asDUX4 (Figures 2B-D). Specifically, in wells treated with U7-asDUX4, there were significantly fewer DUX4-positive cells and / or reduced DUX4 staining intensity in cells that still showed DUX4 signaling (Figures 2B-D). No DUX4 signaling was observed in untransfected HEK293 cells (Figure 2E), while abundant signaling was evident in cells stained with a probe for the peptidyl isomerase B (PPIB) gene, the positive control in the RNAscope assay (Figure 2F), indicating that the positive and negative controls functioned as expected. Consistent with DUX4 knockdown, which provided some protection from cell death (Figure 1D), wells transfected with the U7-asDUX4 plasmid had a higher cell density compared to samples transfected with "DUX4 alone".
[0159] Example 4 U7-asDUX4snRNA reduces full-length DUX4 protein in transfected HEK293 cells. To confirm full-length DUX4 mRNA knockdown, the efficiency of U7-asDUX4 in repressing DUX4 protein expression was determined. To do this, cells were co-transfected with either three read U7-asDUX4 constructs or an untargeted control along with the CMV.DUX4 expression plasmid. To facilitate protein detection, a full-length DUX4 construct containing an intraframe COOH-terminus fusion of the V5 epitope tag (CMV.DUX4.V5-fl) was used (Figure 3A). To detect the DUX4 protein, cells were stained with a fluorescently labeled antibody against the V5 tag. Reduced DUX4.V5 signaling was observed in cells co-transfected with U7-asDUX4 sequence 7 or 8 compared to cells receiving the untargeted control U7-snRNA (Figure 3B). Interestingly, U7-asDUX4-4 did not affect DUX4.V5 protein levels when its binding site was disrupted by the V5 epitope tag, thereby functioning as an incidental control of specificity.
[0160] To further confirm DUX4 protein knockdown by lead U7-snRNA, similar simultaneous transfection experiments were performed in HEK293 cells, with results measured using Western blotting. In addition, different DUX4 expression constructs were used in this series of experiments because the C-terminal V5 tag disrupted the U7-asDUX4-4 binding site. Specifically, a CMV.DUX4 expression plasmid containing an intraframe myc epitope tag at the amino terminus was constructed (Figure 3C). This construct was inferred to allow determination of whether the U7-asDUX4 sequence, designed to mask the full-length DUX4 mRNA SD / SA near the 3' end of exon 1, produces a non-toxic DUX4-s protein isoform that is cleaved with biased splicing (Figure 3C) (Snider et al. (2010) PLoS Genet6, e1001181). Western blotting was performed using protein extracts from HEK293 cells co-transfected with a plasmid expressing Myc.DUX4 and five different U7-asDUX4 constructs, including three read constructs and sequences 5 and 6, designed to form base pairs near the exon 1 / intron 1 junction. Using a myc-epitope antibody, a full-length Myc-DUX4 protein band (52 kDa) was detected in all transfected cells. Furthermore, all samples contained larger non-DUX4 proteins that migrated to the size of the endogenous c-myc protein (approximately 60 kDa). Consistent with previous experiments, the read constructs U7-asDUX4 sequences 4, 7, and 8 significantly reduced DUX4 protein at 87.4%±9.8% SEM, 65.9%±15% SEM, and 84.7%±13.5% SEM (n=3 independent experiments, Figures 3D-E and 6A-B). No evidence of DUX4-s production was detected by Western blotting (predicted size 22 kDa), suggesting that reduction of full-length DUX4 gene expression by U7-asDUX4 sequences (4, 5, 6, and 7), designed to mask the DUX4 splice site, did not function by shifting the splicing pattern to favor the DUX4-s isoform.Similarly, no evidence for the shorter DUX4-s transcript was found using 3'RACE RT-PCR (Figure 7). The nonspecific upper bands in these Western blots indicated variable expression. Since DUX4 has been shown to activate Myc, altering DUX4 levels, if it is Myc, could potentially affect the abundance of its upper band (Shadle et al. (2017) PLoS Genet 13, e1006658). However, no strong correlation was observed between residual DUX4 and Myc abundance in these experiments.
[0161] Example 5 U7-asDUX4 significantly reduces endogenous DUX4 expression in myotubes from FSHD patients. Results from testing in HEK293 suggested that some U7-asDUX4 snRNAs can reduce full-length DUX4 expression and protect against cell death in overexpression models. Therefore, the ability of lead U7-asDUX4 snRNA constructs (4, 7, and 8) to reduce endogenous DUX4 mRNA in the myotubes of FSHD patients was evaluated using RNAscope in situ hybridization. RNAscope has already been used to detect DUX4 in FSHD myotubes (Amini Chermahini et al. (2019) RNA25, 1211-1217). Consistent with previous reports, DUX4 staining was observed to be present in only a small percentage of cells at any given time point. Importantly, we were able to quantify DUX4 knockdown after delivery of the artificial DUX4-targeted microRNA (mi405) (Amini Chermahini et al. (2019) above, Jones et al. (2012) Hum Mol Genet 21, 4419-4430). Therefore, we used RNAscope to determine whether U7-asDUX4 snRNA could reduce endogenous DUX4 signaling in myotubes derived from human FSHD patients, thereby supporting the potential transcriptional potential of this approach. To do this, FSHD myotubes were transfected using electroporation, which typically yields a transfection efficiency of about 50–70% (Figure 8). Consistent with previous results, untransfected 15A FSHD myotubes showed a brown DUX4 signal, while those transfected with U7-asDUX4 sequences 4, 7, and 8 showed a significant reduction in RNAscope signaling (Figures 4A–H). These results confirm that these three U7-asDUX4 constructs (i.e., U7-asDUX4 sequences 4, 7, and 8) can influence the destabilization and degradation of endogenous DUX4 mRNA in FSHD myocytes.
[0162] Example 6 U7-asDUX4snRNA reduces the expression of DUX4 activation biomarkers in FSHD myotubes. With the emergence of prospective FSHD therapies, the FSHD field has seen a need to develop clinical outcome measures and biomarkers that can be used to establish therapeutic efficacy (LoRusso et al. (2019) BMC Neurol 19, 224, Mul et al. (2017) Neurology 89, 2057-2065, Wang et al. (2019) Hum Mol Genet 28, 476-486, Wong et al. (2020) Hum Mol Genet 29, 1030-1043). DUX4 expression is the most direct measure of target involvement by prospective drug or gene therapy, but it is difficult to detect in FSHD muscle biopsies and is relatively low. Therefore, DUX4 expression in human muscle biopsies is not currently a reliable outcome measure for FSHD clinical trials, and some groups are now shifting to testing DUX4 activation biomarkers as an indirect measure of DUX4 expression. At least 67 different genes contain regulatory regions with DUX4 binding sites that are consistently activated upon DUX4 expression. However, recent studies suggest that only a few biomarkers are needed to represent the entire set (Rickard et al. (2015) Hum Mol Genet 24, 5901-5914, Yao et al. (2014) Hum Mol Genet 23, 5342-5352, Eidahl (2016) Hum Mol Genet 25, 4577-4589, Geng et al. (2012) Dev Cell 22, 38-51, Jagannathan (2016) Hum Mol Genet 25, 4419-4431, van den Heuvel et al. (2019) Hum Mol Genet 28, 1064-1075).Therefore, four biomarkers, namely ZSCAN4, PRAMEF12, TRIM43, and MBD3L2, were selected for this study because they are established DUX4 target genes and FSHD disease biomarkers, and consistently show differential expression between FSHD cells and healthy control cells (Yao et al. (2014) Hum Mol Genet 23, 5342-5352, Eidahl (2016) Hum Mol Genet 25, 4577-4589, Chen et al. (2016) Mol Ther 24, 1405-1411, Lek et al. (2020) Sci Transl Med 12, Amini Chermahini (2019) RNA 25, 1211-1217). Accordingly, we tested the ability of several U7-asDUX4 snRNAs to suppress these DUX4 activation biomarkers in FSHD patient cells.
[0163] To do this, myoblasts from 15A FSHD patients were transfected with U7-asDUX4 snRNA-4, -7, and -8, as well as an untargeted control. The cells were then differentiated into myotubes for 7 days, and quantitative RT-PCR was performed to measure the expression of the DUX4-activating human biomarkers TRIM43, MBD3L2, PRAMEF12, and ZSCAN4. The expression of all four biomarkers was present in untreated 15A myotubes and significantly decreased in U7-asDUX4-treated 15A cells (Figure 4I).
[0164] Several U7-asDUX4 constructs were identified that significantly reduced DUX4 and DUX4-related outcomes in both co-transfected cells and myotubes derived from FSHD patients. These experiments provide proof of concept for DUX4 silencing using novel recombinant U7-asDUX4 as a novel approach for the treatment of FSHD. Translating this in vivo approach to an FSHD mouse model is currently underway.
[0165] Example 7 U7-asDUX4snRNA reduces the expression of DUX4 activation biomarkers in mouse models of FSHD. The AAV.U7-asDUX4 of this disclosure was intramuscular (IM) or intravenous (IV) injectable particles of a novel FSHD mouse model, e.g., a tamoxifen-inducible DUX4 (TIC-DUX4) mouse model with severe FSHD (Giesige et al., JCI Insight. 2018; 3(22)), or any other mouse model of FSHD mice. The animals received 3 × 10¹⁴ vg / kg, 8 × 10¹³ vg / kg, or 3 × 10¹³ vg / kg of AAV6 vectors carrying the mi405, mi405H, or miLacZ sequence, or saline via the tail vein or intramuscularly.
[0166] Animals were randomized and injected in a blinded manner, which required two operators: the first to set up the blind and dilute the vector for delivery, and the second to inject the animals and administer the outcome measure. Based on power analysis performed in published characterizations of TIC-DUX4 mice, N=20 animals per group provided sufficient power to test the outcome measure. However, as with humans, TIC-DUX4 mice can exhibit variable phenotypes; therefore, to ensure high power testing and prevent reduction, N is increased to 26 (N=13 males and 13 females) for each dose and time point.
[0167] In some studies, animals are randomly divided into two groups as follows: Acute FSHD model. TIC-DUX4 mice or WT mice treated with tamoxifen (5 mg / kg once weekly for 10 weeks) or sunflower oil vehicle via oral gastric tube.
[0168] A chronic FSHD model. TIC-DUX4 mice or WT mice are left uninduced and can be aged for 9 months before performing outcome measures. At weeks 4, 8, 12, 16, 20, and 24, the expression levels of DUX4 biomarkers such as Wfdc3 or Trim36 are measured by qRT-PCR, RNAscope, or ddPCR.
[0169] A decrease in DUX4 biomarker expression levels was observed in the muscles of mice treated with U7-asDUX4 compared to the muscles of untreated mice. Example 8 U7-asDUX4snRNA reduces endogenous DUX4 expression in muscle in a mouse model of FSHD. The AAV.U7-asDUX4 described herein is injected intramuscularly (IM) or intravenously (IV) into a novel FSHD mouse model (TIC-DUX4) or any other mouse model of FSHD mice. After 4, 8, 12, 16, 20, and 24 weeks, the expression level of DUX4 mRNA is measured by qRT-PCR, RNAscope, or ddPCR. Several muscles, including the tibialis anterior, gastrocnemius, triceps, biceps, quadriceps, and diaphragm, are collected for histopathological and molecular analysis. Absolute and specific strength measurements are performed in the gastrocnemius. Since strength measurements may negatively affect the integrity of muscle histopathology (i.e., making them of non-public quality for imaging), several extra mice are optionally injected into each group to ensure high-quality images for histopathological analysis.
[0170] A decrease in DUX4 mRNA levels is observed in the muscles of mice treated with U7-asDUX4 compared to the muscles of untreated mice. Example 9 U7-asDUX4snRNA reduces endogenous DUX4 expression in muscle. The AAV.U7-asDUX4 described herein is administered intramuscularly (IM) or intravenously (IV) to patients suffering from FSHD. The expression level of DUX4 mRNA in the patient's muscle is measured in biopsy muscle by qRT-PCR, RNAscope, or ddPCR before treatment and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks after treatment.
[0171] A decrease in DUX4 mRNA levels is observed in the muscles of patients treated with U7-asDUX4, compared to the levels of DUX4 mRNA in the muscles of the same patients before treatment. Improvement in FSHD disease symptoms is also observed.
[0172] The foregoing explanation is given solely for clarity of understanding, and modifications within the scope of the invention may be obvious to those skilled in the art; therefore, no unnecessary limitations should be inferred therefrom. Throughout this specification and the subsequent claims, unless otherwise required by context, the word “comprise” and variations such as “comprises” and “comprising” should be understood to mean including the integer or step or group of integers or steps described, but not to mean excluding any other integer or step or group of integers or steps.
[0173] Throughout this specification, where a composition is described as comprising components or materials, unless otherwise stated, the composition is intended to consist essentially of, or comprise, any combination of the listed components or materials. Similarly, where a method is described as comprising certain steps, unless otherwise stated, the method is also intended to consist essentially of, or comprise, any combination of the listed steps. The inventions disclosed herein by example can be adequately carried out without any elements or steps not specifically disclosed herein.
[0174] The methods disclosed herein, and their individual steps, can be carried out manually and / or with the assistance of electronic devices or automation provided thereby. Although the processes are described with reference to specific embodiments, those skilled in the art will readily understand that other methods can be used to perform the actions related to the methods. For example, various orders of the steps can be changed without departing from the scope or spirit of the methods unless otherwise stated. In addition, some of the individual steps can be combined, omitted, or subdivided into further additional steps.
[0175] All patents, publications, and references cited herein are incorporated entirely by reference. In the event of any conflict between this disclosure and the incorporated patents, publications, and references, this disclosure shall prevail. The numbered references referred herein are provided together with all cited references as shown below.
[0176] References 1. Deenen, JC, Arnts, H., van der Maarel, SM, Padberg, GW, Verschuuren, JJ, Bakker, E., Weinreich, SS, Verbeek, AL, and van Engelen, BG (2014). Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 83, 1056-1059. 2.Pastorello, E., Cao, M., and Trevisan, CP (2012).Atypical onset in a series of122 cases with FacioScapuloHumeral Muscular Dystrophy.Clin Neurol Neurosurg114, 230-234. 3.Klinge,L.,Eagle,M.,Haggerty,ID,Roberts,CE,Straub,V.,and Bushby,KM(2006).Severe phenotype in infantile facioscapulohumeral muscular dystrophy.Neuromuscul Disord16,553-558. 4.Statland,JM,and Tawil,R.(2016).Facioscapulohumeral Muscular Dystrophy.Continuum(Minneap Minn)22,1916-1931. 5.Lemmers,RJ,van der Vliet,PJ,Klooster,R.,Sacconi,S.,Camano,P.,Dauwerse,JG,Snider,L.,Straasheijm,KR,van Ommen,GJ,Padberg,GW,et al.(2010).A unifying genetic model for facioscapulohumeral muscular dystrophy.Science329,1650–1653. 6.Hendrickson, PG, Dorais, JA, Grow, EJ, Whiddon, JL, Lim, JW, Wike, CL, Weaver, BD, Pflueger, C., Emery, BR, Wilcox, AL, et al retrotransposons.Night Genes49,925–934. Nat Genet49,935-940: Conservation and innovation in the DUX4 family gene network.Nat Genet49,935-940. 8.Bosnakovski, D., Xu, Z., Gang, EJ, Galindo, CL, Liu, M., Simsek, T., Garner, HR, Agha-Mohammadi, S., Tassin, A., Coppee, F., et al pathologies.EDUCATION J27,2766-2779. 9.Dixit, M., Ansseau, E., Tassin, A., Winokur, S., Shi, R., Qian, H., Sauvage, S., Matteotti, C., van Acker, AM, Leo, O., et al PITX1.Proc Natl Acad Sci USA 104,18157–18162. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo Neurol69,540–552. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of 11.Giesige, CR, Wallace, LM, Heller, KN, NY, Fowler, AM, Pyne, NK, Al-Kharsan, M., Rashnonejad, A., Chermahini, GA, et al FSHD.JCI Insight3. 12.Kowaljow, V., Marcowycz, A., Ansseau, E., Conde, CB, Sauvage, S., Matteotti, C., Arias, C., Corona, ED, Nunez, NG, Leo, O., et al Disord17,611–623. 13.Snider, L., Asawachaicharn, A., Tyler, AE, Geng, LN, Petek, LM, Maves, L., Miller, DG, Lemmers, RJ, Winokur, ST, Tawil, R., et al Pathophysiology of facioscapulohumeral dystrophy.Hum Mol Genet18,2414–2430. 14.Snider,L.,Geng,LN,Lemmers,RJ,Kyba,M.,Ware,CB,Nelson,AM,Tawil,R,Filippova,GN,van der Maarel,SM,Tapscott,SJ,et al.(2010).Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.PLoS Genet6,e1001181. 15.Shadle, SC, Zhong, JW, Campbell, AE, Conerly, ML, Jagannathan, S., Wong, CJ, Morello, TD, van der Maarel, SM, and Tapscott, SJ(2017).DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy.PLoS Genet13,e1006658. 16.Dmitriev, P., Bou Saada, Y., Dib, C., Ansseau, E., Barat, A., Hamade, A., Dessen, P., Robert, T., Lazar, V., Louzada, RAN, et al Free Radic Biol Med99,244–258. 17.Rickard,A.M.,Petek,L.M.,and Miller,D.G.(2015).Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways.Hum Mol Genet24,5901-5914. 18.Vanderplanck,C.,Ansseau,E.,Charron,S.,Stricwant,N.,Tassin,A.,Laoudj-Chenivesse,D.,Wilton,S.D.,Coppee,F.,and Belayew,A.(2011).The FSHD atrophic myotube phenotype is caused by DUX4 expression.PLoS One6,e26820. 19.Yao,Z.,Snider,L.,Balog,J.,Lemmers,R.J.,Van Der Maarel,S.M.,Tawil,R.,and Tapscott,S.J.(2014).DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.Hum Mol Genet23,5342-5352. 20.Eidahl,J.O.,Giesige,C.R.,Domire,J.S.,Wallace,L.M.,Fowler,A.M.,Guckes,S.M.,Garwick-Coppens,S.E.,Labhart,P.,and Harper,S.Q.(2016).Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4.Hum Mol Genet25,4577-4589. 21.Lyle,R.,Wright,T.J.,Clark,L.N.,and Hewitt,J.E.(1995).The FSHD-associated repeat,D4Z4,is a member of a dispersed family of homeobox-containing repeats,subsets of which are clustered on the short arms of the acrocentric chromosomes.Genomics28,389-397. 22.Gabriels,J.,Beckers,M.C.,Ding,H.,De Vriese,A.,Plaisance,S.,van der Maarel,S.M.,Padberg,G.W.,Frants,R.R.,Hewitt,J.E.,Collen,D.,et al.(1999).Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each3.3 kb element.Gene236,25-32. 23.Marsollier,A.C.,Ciszewski,L.,Mariot,V.,Popplewell,L.,Voit,T.,Dickson,G.,and Dumonceaux,J.(2016).Antisense targeting of3’ end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy:a new gene-silencing approach.Hum Mol Genet25,1468-1478. 24.Chen,J.C.,King,O.D.,Zhang,Y.,Clayton,N.P.,Spencer,C.,Wentworth,B.M.,Emerson,C.P.,Jr.,and Wagner,K.R.(2016).Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.Mol Ther24,1405-1411. 25.Ansseau,E.,Vanderplanck,C.,Wauters,A.,Harper,S.Q.,Coppee,F.,and Belayew,A.(2017).Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy(FSHD).Genes(Basel)8. 26.Lek,A.,Zhang,Y.,Woodman,K.G.,Huang,S.,DeSimone,A.M.,Cohen,J.,Ho,V.,Conner,J.,Mead,L.,Kodani,A.,et al.(2020).Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.Sci Transl Med12. 27.Himeda,C.L.,Jones,T.I.,and Jones,P.L.(2016).CRISPR / dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.Mol Ther24,527-535. 28.DeSimone,A.M.,Leszyk,J.,Wagner,K.,and Emerson,C.P.,Jr.(2019).Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy.Sci Adv 5,eaaw7099. 29.Lim,K.R.Q.,Maruyama,R.,Echigoya,Y.,Nguyen,Q.,Zhang,A.,Khawaja,H.,Sen Chandra,S.,Jones,T.,Jones,P.,Chen,Y.W.,et al.(2020).Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy.Proc Natl Acad Sci U S A 117,16509-16515. 30.Amini Chermahini,G.,Rashnonejad,A.,and Harper,S.Q.(2019).RNAscope in situ hybridization-based method for detecting DUX4 RNA expression in vitro.RNA25,1211-1217. 31.Wallace,L.M.,Saad,N.Y.,Pyne,N.K.,Fowler,A.M.,Eidahl,J.O.,Domire,J.S.,Griffin,D.A.,Herman,A.C.,Sahenk,Z.,Rodino-Klapac,L.R.,et al.(2018).Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD.Mol Ther Methods Clin Dev8,121-130. 32.Verma,A.(2018).Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.Ann Indian Acad Neurol21,3-8. 33.Ideue,T.,Adachi,S.,Naganuma,T.,Tanigawa,A.,Natsume,T.,and Hirose,T.(2012).U7small nuclear ribonucleoprotein represses histone gene transcription in cell cycle-arrested cells.Proc Natl Acad Sci U S A 109,5693-5698. 34.Schumperli,D.,and Pillai,R.S.(2004).The special Sm core structure of the U7 snRNP:far-reaching significance of a small nuclear ribonucleoprotein.Cell Mol Life Sci61,2560-2570. 35.Goyenvalle,A.,Babbs,A.,van Ommen,G.J.,Garcia,L.,and Davies,K.E.(2009).Enhanced exon-skipping induced by U7snRNA carrying a splicing silencer sequence:Promising tool for DMD therapy.Mol Ther17,1234-1240. 36.Goyenvalle,A.,Wright,J.,Babbs,A.,Wilkins,V.,Garcia,L.,and Davies,K.E.(2012).Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.Mol Ther20,1212-1221. Restoration of correct beta(IVS2-654)-globin mRNA splicing and HbA production by engineered U7snRNA in beta-thalassaemia / HbE erythroid cells.Sci Rep9.7672. 38.Biferi, MG, Cohen-Tannoudji, M., Cappelletto, A., Giroux, B., Roda, M., Astord, S., Marais, T., Bos, C., Voit, T., Ferry, A., et al in an ALS Mouse Model.Mol Ther25,2038–2052. [ PMC free article ] [ PubMed ] 39.Wein, N., Vulin, A., Falzarano, MS, Szigyarto, CA, Maiti, B., Findlay, A., Heller, KN, Uhlen, M., Bakthavachalu, B., Messina, S., et al Dystrophinopathy in humans and mice.Nat Med20,992-1000. 40.Jones,T.I.,Chen,J.C.,Rahimov,F.,Homma,S.,Arashiro,P.,Beermann,M.L.,King,O.D.,Miller,J.B.,Kunkel,L.M.,Emerson,C.P.,Jr.,et al.(2012).Facioscapulohumeral muscular dystrophy family studies of DUX4 expression:evidence for disease modifiers and a quantitative model of pathogenesis.Hum Mol Genet21,4419-4430. 41.LoRusso,S.,Johnson,N.E.,McDermott,M.P.,Eichinger,K.,Butterfield,R.J.,Carraro,E.,Higgs,K.,Lewis,L.,Mul,K.,Sacconi,S.,et al.(2019).Clinical trial readiness to solve barriers to drug development in FSHD(ReSolve):protocol of a large,international,multi-center prospective study.BMC Neurol19,224. 42.Mul,K.,Vincenten,S.C.C.,Voermans,N.C.,Lemmers,R.,van der Vliet,P.J.,van der Maarel,S.M.,Padberg,G.W.,Horlings,C.G.C.,and van Engelen,B.G.M.(2017).Adding quantitative muscle MRI to the FSHD clinical trial toolbox.Neurology89,2057-2065. 43.Wang,LH,Friedman,SD,Shaw,D.,Snider,L.,Wong,CJ,Budech,CB,Poliachik,SL,Gove,NE,Lewis,LM,Campbell,AE,et al.(2019).MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.Hum Mol Genet28,476-486. 44.Wong,CJ,Wang,LH,Friedman,SD,Shaw,D.,Campbell,AE,Budech,CB,Lewis,LM,Lemmers,R.,Statland,JM,van der Maarel,SM,et al.(2020).Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies.Hum Mol Genet29,1030-1043. 45.Geng,LN,Yao,Z.,Snider,L.,Fong,AP,Cech,JN,Young,JM,van der Maarel,SM,Ruzzo,WL,Gentleman,RC,Tawil,R.,et al.(2012).DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.Dev Cell22,38-51. 46.Jagannathan, S., Shadle, SC, Resnick, R., Snider, L., Tawil, RN, van der Maarel, SM, Bradley, RK, and Tapscott, SJ(2016). 47.van den Heuvel, A., Mahfouz, A., Cloet, SL, Balog, J., van Engelen, BGM, Tawil, R., Tapscott, SJ, and van der Maarel, SM(2019).Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.Hum Mol Genes28,1064–1075. DUX4 differentially regulates the transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.PLoS One8,e64691. 49.Rojas, LA, Valentine, E., Accorsi, A., Maglio, J., Shen, N., Robertson, A., Kazmirski, S., Rahl, P., Tawil, R., Cadavid, D., et al Dystrophy.J Pharmacol Exp Ther.374(3):489–498. 50.Wein,N.,Vulin,A.,Findlay,A.R.,Gumienny,F.,Huang,N.,Wilton,S.D.,and Flanigan,K.M.(2017).Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.J Neuromuscul Dis4,199-207. 51.Voit,T.,Topaloglu,H.,Straub,V.,Muntoni,F.,Deconinck,N.,Campion,G.,De Kimpe,S.J.,Eagle,M.,Guglieri,M.,Hood,S.,et al.(2014).Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy(DEMAND II):an exploratory,randomised,placebo-controlled phase2 study.Lancet Neurol13,987-996. 52.Kinali,M.,Arechavala-Gomeza,V.,Feng,L.,Cirak,S.,Hunt,D.,Adkin,C.,Guglieri,M.,Ashton,E.,Abbs,S.,Nihoyannopoulos,P.,et al.(2009).Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy:a single-blind,placebo-controlled,dose-escalation,proof-of-concept study.Lancet Neurol8,918-928. 53.Mendell,J.R.,Goemans,N.,Lowes,L.P.,Alfano,L.N.,Berry,K.,Shao,J.,Kaye,E.M.,Mercuri,E.,Eteplirsen Study,G.,and Telethon Foundation,D.M.D.I.N.(2016).Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.Ann Neurol79,257-271. 54.Carrell,S.T.,Carrell,E.M.,Auerbach,D.,Pandey,S.K.,Bennett,C.F.,Dirksen,R.T.,and Thornton,C.A.(2016).Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.Hum Mol Genet25,4328-4338. 55.Aoki,Y.,Nagata,T.,Yokota,T.,Nakamura,A.,Wood,M.J.,Partridge,T.,and Takeda,S.(2013).Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice.Hum Mol Genet22,4914-4928. 56.Heemskerk, H., de Winter, C., van Kuik, P., Heuvelmans, N., Sabatelli, P., Rimessi, P., Braghetta, P., van Ommen, GJ, de Kimpe, S., Ferlini, A., et al antisense oligonucleotides in the mdx mouse model.Mol Ther18,1210–1217. 57.Shimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., and Aoki, Y. (2019). 58.Gonzalez-Barriga,A.,Kranzen,J.,Croes,HJ,Bijl,S.,van den Broek,WJ,van Kessel,ID,van Engelen,BG,van Deutekom,JC,Wieringa,B,Mulders,SA,et al.(2015).Cell membrane integrity in myotonic dystrophy type1:implications for therapy.PLoS One10,e0121556. U7snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping 59.Brun, C., Suter, D., Pauli, C., Dunant, P., Lochmuller, H., Burgunder, JM, Schumperli, D., and Weis, J. (2003).Cell Mol Life Sci60,557-566. 60. Stadler, G., Rahimov, F., King, OD, Chen, JC, Robin, JD, Wagner, KR, Shay, JW, Emerson, CP, Jr., and Wright, WE (2013). Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. Nat Struct Mol Biol20, 671-678. 61. Liu, J., and Gall, JG (2007). U bodies are cytoplasmic structures that contain uridine-rich small nuclear ribonucleoproteins and associate with P bodies. PNAS104(28), 11655-11659. This disclosure describes specific embodiments found to include or proposed to include a particular scheme for carrying out the disclosure. Various modifications and variations of this disclosure will be apparent to those skilled in the art without departing from the scope and spirit of this disclosure. While this disclosure describes specific embodiments, it should be understood that the claimed methods of this disclosure should not be unduly limited to such specific embodiments. In fact, various modifications of the described schemes for carrying out methods that would be apparent to those skilled in the art are intended to be within the scope of the following claims.
Claims
1. A nucleic acid encoding a U7 double homeobox 4 (DUX4) antisense ribonucleic acid (asRNA), (a) a nucleotide sequence that contains at least 90% identity to a sequence set forth in any one of SEQ ID NOs: 1 to 18; (b) a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 18; or (c) a nucleic acid comprising a combination of the nucleotide sequences of (a) and / or (b).
2. A nucleic acid comprising a nucleotide sequence encoding a U7DUX4 antisense sequence that specifically hybridizes to a dual homeobox 4 (DUX4) target nucleotide sequence set forth in any one of SEQ ID NOs: 19-36 or a combination of said nucleotide sequences.
3. The nucleic acid of claim 1 or 2, further comprising a promoter nucleotide sequence.
4. 4. The nucleic acid of claim 3, wherein the promoter is any of a U6 promoter, a U7 promoter, a tRNA promoter, an H1 promoter, a minimal CMV promoter, a T7 promoter, an EF1-alpha promoter, a minimal EF1-alpha promoter, or a muscle-specific promoter.
5. 5. The nucleic acid of claim 4, wherein the muscle-specific promoter is an unc45b promoter, a tMCK promoter, a minimal MCK promoter, a CK6 promoter, a CK7 promoter, an MHCK7 promoter, or a CK1 promoter.
6. A nanoparticle, extracellular vesicle, exosome, or vector comprising the nucleic acid of any one of claims 1 to 5 or any combination of one or more thereof.
7. The vector of claim 6 , wherein the vector is a viral vector.
8. 8. The viral vector of claim 7, wherein the viral vector is an adeno-associated virus (AAV), an adenovirus, a lentivirus, a retrovirus, a poxvirus, a baculovirus, a herpes simplex virus, a vaccinia virus, or a synthetic virus.
9. The viral vector according to claim 7 or 8, wherein the viral vector is an AAV.
10. The viral vector of claim 9 , wherein the AAV lacks the rep and cap genes.
11. The viral vector of claim 9 or 10, wherein the AAV is a recombinant AAV (rAAV) or a self-complementary recombinant AAV (scAAV).
12. The viral vector according to any one of claims 9 to 11, wherein the AAV is rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, rAAV11, rAAV12, rAAV13, rAAV-anc80, rAAVrh.74, rAAVrh.8, rAAVrh.10, or rAAV-B1.
13. The viral vector according to any one of claims 9 to 12, wherein the AAV is rAAV-9.
14. 1. A composition comprising: (a) a nucleic acid according to any one of claims 1 to 5; (b) the nanoparticle, extracellular vesicle, exosome, or vector according to claim 6; or (c) a viral vector according to any one of claims 7 to 13; and a pharma- ceutically acceptable carrier.
15. 15. The composition of claim 14 for inhibiting and / or interfering with the expression of the double homeobox 4 (DUX4) gene in a cell.
16. The composition of claim 14 for treating a subject with muscular dystrophy.
17. 17. The composition of claim 16, wherein the muscular dystrophy is facioscapulohumeral muscular dystrophy (FSHD).
18. The composition of claim 14 for treating a subject with cancer.
19. The composition of claim 18 , wherein the cancer is a sarcoma.
20. A use for the preparation of a pharmaceutical agent for inhibiting expression of the dual homeobox 4 (DUX4) gene in a cell, comprising: (a) a nucleic acid according to any one of claims 1 to 5; (b) the nanoparticle, extracellular vesicle, exosome, or vector according to claim 6; or (c) The viral vector according to any one of claims 7 to 13. Use of.
21. Use for the preparation of a pharmaceutical for treating or ameliorating muscular dystrophy, comprising: (a) a nucleic acid according to any one of claims 1 to 5; (b) the nanoparticle, extracellular vesicle, exosome, or vector according to claim 6; or (c) The viral vector according to any one of claims 7 to 13. Use of.
22. 22. The use according to claim 21, wherein the muscular dystrophy is facioscapulohumeral muscular dystrophy.
23. Use for the preparation of a medicine for treating or ameliorating cancer, comprising: (a) a nucleic acid according to any one of claims 1 to 5; (b) the nanoparticle, extracellular vesicle, exosome, or vector according to claim 6; or (c) The viral vector according to any one of claims 7 to 13. Use of.
24. 24. The use of claim 23, wherein the cancer is a sarcoma.
25. The composition of any one of claims 14 to 19, formulated for intramuscular injection, transdermal delivery, or injection into the bloodstream.
26. The use of any one of claims 20 to 24, wherein the pharmaceutical agent is formulated for intramuscular injection, transdermal delivery, or injection into the bloodstream.
